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1 Introduction 
1.1 Natural products in therapeutic use 
Throughout many years, natural products have been playing a major role in the search for 
novel drugs or drug candidates. They are an ongoing and inspiring source for researchers due 
to their enormous structural diversity and complexity. Today, more than 50 % of the drugs 
prescribed in the USA are natural products or semisynthetic derivatives thereof (Schneider et 
al., 2008). In addition, a number of chemicals used in crop protection are also of natural 
origin. 
S
30%
S/NM
11%S*
5%
S*/NM
11%
V
4%
B
12%
N
4%
ND
23%
 
Figure 1-1-1:  New chemical entities in the time frame 1981 – 2006 
“B” Biological; usually a large (> 45 residues) peptide or protein, generally isolated from an organism/cell 
line or produced by biotechnological means in a surrogate host; “N” Natural product; “ND” Derived from 
a natural product, usually a semisynthetic modification; ”S” Totally synthetic drug, mostly found by 
random screening or modification of an existing agent; “S*” Made by total synthesis, but the 
pharmacophore is/was from a natural product; “V” Vaccine; “NM” Natural Product mimic. (Taken from 
Newman & Cragg, 2007) 
 
The most prominent producers of natural products can be found within three groups of 
organisms: plants, bacteria, mainly actinomycetales, myxobacteria and cyanobacteria, and 
fungi. From all these groups, a plethora of exciting compounds belonging to diverse 
biogenetic families has been isolated. While plants and plant extracts have been playing an 
important role in traditional medicine for thousands of years, the discovery and investigation 
of bacterial and fungal natural products had only been made possible with the development of  
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natural sciences during the 20th century. However, especially since the discovery of penicillin 
in 1929 and the following “Golden Age of Antibiotics”, as the period from 1940 to the 1970s 
has often been described, metabolites of microbial origin are well known as valuable supply 
of new compounds and lead structures in the quest for drug candidates against infectious 
diseases, cancer and many other illnesses (Newman & Cragg, 2007; Koehn & Carter, 2005). 
Among them are therapeutically used alkaloids like ergotamine, the immunosuppressive 
peptide cyclosporine A, other peptidic compounds like the penicillins and cephalosporins, the 
polyketide lovastatin and the antibacterial terpenoid fusidic acid (Fig. 1-1-2). 
 
During the last decades, more and more efforts have been undertaken by researchers in the 
search for drugs against cancer, seeing that the disease is becoming a major cause of death 
among the population of developed countries (Szekeres & Novotny, 2002). The various forms 
of cancer require multiple approaches for their treatment, which opens a wide field of research 
that has to be explored. Natural products have therefore been recognized as one promising 
source for antitumor compounds. A substantial amount of research into cytotoxic natural 
products has been carried out in the last 50 years, and significant advances in cancer treatment 
have been achieved (da Rocha et al., 2001).  
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Figure 1-1-2:  fungal secondary metabolites used as therapeutic agents 
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1.2 Cytotoxic natural products  
1.2.1 Cytotoxic natural products in therapeutic use 
Cytotoxic compounds that are in clinical use as antitumor drugs represent an immense variety 
of structural types, according to the many different targets focused on in the drug therapy of 
cancer. Within this group of compounds, natural products still play an important role and have 
been proven to be valuable tools for the development of new anti-cancer drugs, but also for 
the antitumor treatment itself.  
 
The alkylating agents represent the biggest group of cytotoxic compounds used in cancer 
treatment.  They possess the ability to form reactive carbenium-ions that attack nucleophilic 
centers of the DNA. The natural product mitomycin C has been isolated from the 
actinobacterium Streptomyces caespitosus in 1956 by Hata and co-workers and is a great 
example for a perfect “drug design” by nature. Mitomycin C is completely inactive in vitro, 
but shows alkylating activity after enzymatic reduction of the chinone to the hydrochinone. 
After elimination of methanol and carbaminate, the nucleophilic attack takes place, while 
undergoing ring opening of the aziridin system. In addition to the cytotoxic activity, 
mitomycin C also possesses antibiotic and antiviral properties (Crooke & Bradner, 1976). 
 
N
O
O
H2N
O NH2
OO
NH
 
 
 
The anthracyclines, e. g. daunorubicin or doxorubicin, form a whole series of natural and 
natural-derived compounds that have also been isolated from Streptomyces spp.. They are 
very commonly used in cancer treatment and act through several mechanisms, e. g. by 
intercalation of DNA, inhibition of DNA synthesis, interaction with the RNA polymerase and 
inhibition of DNA-topoisomerase II (Minotti et al., 2004). Inhibition of type I or type II 
topoisomerases interferes with both transcription and replication of DNA by upsetting proper 
DNA supercoiling.  
mitomycin C 
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The very complex structure of paclitaxel (Taxol®) has been isolated in the 1960s from Taxus 
brevifolia (Wani et al., 1971). It is an inhibitor of the mitosis process in cells. Paclitaxel 
interferes with the normal function of microtubule breakdown and arrests the microtubule 
function by hyper-stabilization of their structure. This destroys the cell's ability to use its 
cytoskeleton in a flexible manner. The resulting microtubule / paclitaxel complex does not 
have the ability to disassemble (McGrogan et al., 2008). 
 
O NH O
O
OH
O
O
O
OH
O
O
O
O
H
O
OH
 
 
Due to its unique structure containing no less than eleven chiral centers, a fast and cost-
effective total synthesis of paclitaxel has not been succeeded yet. In 1993, Stierle and co-
workers discovered that taxol was coincidentally produced in a newly described fungus living 
in the yew tree (Stierle et al., 1993). Since, it has been found in a number of other endophytic 
fungi, opening the possibility of taxol production by culturing one of these fungal species and 
daunorubicin 
paclitaxel 
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thus reducing time and cost for production of the compound (Ge et al., 2004; Yuan et al., 
2006). Paclitaxel can thus be considered as the first cytotoxic fungal secondary metabolite in 
clinical use. 
 
Comparably to paclitaxel, the aryltetralignan podophyllotoxin has been reported to be 
produced by endophytes, namely Phialocephela fortinii, isolated from the rhizomes of the 
host plant Podophyllum peltatum (Eyberger et al., 2006). 
O
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Podophyllotoxin, which was originally isolated from the rhizoma of Podophyllum peltatum, is 
a valuable natural product as precursor for several therapeutic agents, including the anticancer 
drugs etoposide, teniposide and etoposide phosphate (Canel et al., 2000). There is an urgent 
demand for other sources than the primary source plant, whose wild populations are being 
destroyed more and more and the pharmaceutical demand will not be covered anymore if no 
other sources are made available (Eyberger et al., 2006).  
The cytotoxic podophyllotoxin analogues in clinical use have been shown to delay transit of 
cells through the S phase and arrest cells in the S phase or early G2 phase. Etoposide is a 
topoisomerase II inhibitor and appears to cause DNA stand breaks (Hainsworth and Greco, 
1995). 
 
 
 
podophyllotoxin etoposide:   R1 = CH3,  R2 = H 
etoposide phosphate:  R1 = CH3,  R2 = PO(OH)2 
teniposide:    R1 =  S  , R2 = H 
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1.2.2 Cytotoxic fungal metabolites as future antitumor agents  
Fungal secondary metabolites play a major role within the large group of natural products 
originating from microorganisms and show a wide range of different bioactivities, such as 
antiinfective, antiproliferative, immunosuppressive, and many more (Misiek & Hoffmeister, 
2007; Schneider et al., 2008). Some substances of fungal origin are not applicable for 
therapeutical use but are known as mycotoxins, e. g. the aflatoxins or the trichothecenes 
(Sweeney & Dobson, 1998). Furthermore, the functions of many molecules have not been 
discovered yet, even though they possess remarkable scaffolds, often including amazing 
stereochemical variations. A large number of fungal secondary metabolites is published 
possessing cytotoxic properties. Like their plant- or bacterium-derived relatives, some of them 
have entered clinical trials while others serve as lead structures in the search for clinically 
applicable antitumor drugs (Siddiq & Dembitsky, 2008).  
A considerable number of natural products have been isolated from marine fungi, albeit that 
the number of bioactive secondary metabolites from fungi in the terrestrial habitat is still 
dominating the diverse spectrum of fungal secondary metabolites. This is because they are 
more thoroughly investigated than their marine relatives and not due to a higher biodiversity 
within the terrestrial habitat (Saleem et al., 2007). However, those fungal secondary 
metabolites already obtained are exemplary for the structures still waiting to be discovered.  
 
1.2.2.1 Cytotoxic fungal metabolites from the terrestrial habitat 
One of the best evaluated fungal metabolites in oncological research is fumagillin. It has been 
isolated from the fungus Aspergillus fumigatus and has created researchers’ interest because 
of its anti-angiogenetic properties (Lu et al., 2006; Kim et al., 2004; Lee et al., 2007). Many 
semisynthetic fumagillin analogues derived from the lead structure have been synthesized in 
order to increase potency and at the same time decrease toxicity. Of these, TNP-470 has 
entered phase I and phase II clinical studies for the treatment of breast, prostate, and brain 
cancer, as well as Kaposi sarcoma (Kruger & Figg, 2000). A second analogue, CKD-732, has 
also entered clinical trials, being even more potent and less toxic than TNP-470 (Lee et al., 
2004; Kim et al., 2007). 
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TNP-470 acts through an irreversible binding to methionine aminopeptidase 2, which then 
leads to intracellular signalling interference (Zhang et al., 2006; Lu et al., 2006). 
As the same antiproliferative mechanism of action might be used for the treatment of 
rheumatoid arthritis, the fumagillin derivative PPI-2485 has been investigated for its effect on 
this. Furthermore, fumagillin and another analogue, ovalicin, have been proven to be highly 
active as antimicrosporidial agents in mice (Didier et al., 2006) and have been found to inhibit 
HIV-1 viral protein R (VPR) activity (Asami et al., 2006). 
 
Illudin S is a highly toxic substance belonging to the sesquiterpenes, which are extremely rare 
in fungi. It was isolated from the homobasidiomycete Omphalotus illudens. Semi-synthetic 
derivatives like irofulvene showed less severe side effects and toxicity whilst still being 
cytotoxic in the MV522 lung carcinoma cell assay with an IC50 value of 73 nM for irofulvene 
(McMorris et al., 2001). Irofulvene possesses a greater efficacy than illudin S due to its 
slower and more selective action. It has entered phase I and II clinical trials against several 
types of cancer, e. g. prostate and ovarian cancer (Seiden et al., 2006). Several other 
acylfulvenes have been isolated or synthetized and are likely to enter clinical studies as well 
(McMorris et al., 1999a; McMorris et al., 1999b). 
fumagillin TNP-470 
CKD-732 
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berkeleyamide D (configuration not published) 
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Irofulvene is an alkylating agent, which is attacked by cellular nucleophiles after being 
activated by reduction of the α,β-unsaturated ketone (Gregerson et al., 2003). The resulting 
adducts lead to inhibition of DNA synthesis, DNA stand breaks, cell cycle arrest and, finally, 
apoptosis. Surprisingly, irofulvene is not affected by DNA repair mechanism enzymes and 
also acts very selective against several human carcinoma cells. This selectivity is due to a fast, 
energy-dependent uptake mechanism existing in sensitive cells (McMorris et al., 2001). 
 
Besides compounds submitted to clinical studies, several fungal metabolites are known to 
date whose promising in vitro antitumor activity makes them interesting candidates for 
preclinical and clinical studies. Stierle and co-workers have isolated the berkeleyamides A-D 
from a deep water Penicillium rubrum (Stierle et al., 2008). The producing strain was derived 
from a flooded open-pit copper mine containing acidic water (pH 2.5) contaminated with high 
concentrations of metal sulphates (iron, copper, aluminium, zinc).  
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N
H
O
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O
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Berkeleyamide D shows a very unusual azaspirocyclic ring system and exhibits promising 
cytotoxic activities with an IC50 value of 0.61 µM. It has been submitted to the NCI/NIH 
Development Therapeutics Program for further preclinical testing (Stierle et al., 2008). 
 
 
illudin S irofulvene 
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chaetominine 
Jiao and co-workers have isolated the tripeptide-derived alkaloid chaetominine from an 
endophytic Chaetomium sp. in 2006. Chaetominine possesses an unprecedented structural 
framework, which is not comparable to any isolated compounds from the host plant 
Adenophora axilliflora, thus underlining the fungal origin of the substance. The compound is 
active against the human leukemia K562 and colon cancer SW1116 cell lines with IC50 values 
of 21 and 28 nM, respectively, which is more potent than the frequently prescribed antitumor 
drug 5-fluorouracil (Jiao et al., 2006).  
N N
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1.2.2.2 Cytotoxic fungal metabolites from the marine habitat 
As the need for new anticancer substances continues, and many well-investigated approaches 
such as combinatorial chemistry only led to minor innovations in drug therapy, the 
investigation of new, rather unexplored sources is one logical consequence in the process of 
searching for new bioactive natural products. The marine ecosystem, covering more than 
70 % of the planet’s surface, is home to an immense diversity of life. Though, due to the 
extreme depth of the oceans, they represent more than 99 % of our planet’s natural habitat 
when setting the terrestrial habitat up to 100 m of height (Schuh, 2008). Compared to the 
research done into terrestrial microorganisms, there is extremely little knowledge about their 
marine relatives. Even though the important antibiotic cephalosporin C has been isolated from 
a marine-derived fungus in the 1940s, research focused on the discovery of marine natural 
products was rare until the 1990s. The almost exponential growth of studies of marine fungi 
led to more than 300 new natural products (Bugni & Ireland, 2004). Most metabolites known 
to date are produced by Aspergilli and Penicillia. Reasons therefore might be that both 
species are somewhat ubiquitous, salt tolerant and fast growing. Several interesting structures 
have been isolated from obligate marine fungi restricted to the marine environment, e. g. the 
antimicrobial alkaloid ascosalipyrrolidinone A from Ascochyta salicorniae (Osterhage et al., 
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2000). However, many facultative marine species that might also occur in freshwater or 
terrestrial habitats often produce compounds similar to those isolated from other 
environments. 
 
 
 
 
 
 
 
 
 
 
The gymnastatins, isolated by Numata and co-workers from a sponge-derived Gymnascella 
dankaliensis are among the first cytotoxic metabolites isolated from a marine-derived fungus. 
Five substructures of these unusual chlorinated polyketides are known to date, that exhibit 
cytotoxic activity in a P388 lympholeukemia test system with an ED50 value of 18 ng mL-1 for 
the most potent gymnastatin A (Numata et al., 1997). It is presumed that the gymnastatins act 
as cytotoxins due to a Michael-acceptor function. 
O
N
H
OH
Cl
Cl
O
O
 
 
 
The leptosin family with 19 members known to date is one of the largest classes of cytotoxic 
fungal metabolites (Bugni & Ireland, 2004). The leptosins are dimeric diketopiperazines 
possessing one or even two polythiobridges, and are related to the terrestrial metabolite 
chaetocin. Their cytotoxic potential against a P388 leukemia cell line ranges from 
1.75 ng mL-1 to low µg mL-1 values, depending on the number of the polythiobridges and 
stereochemical effects. 
  
gymnastatin A 
Ascosalipyrrolidinone A 
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Leptosins A and C showed significant antitumor activity in mice with Sarcoma-180 ascites 
while leptosin M revealed to be a potent inhibitor of topoisomerase II, and two kinases, PTK 
and CaMKIII (Yanagihara et al., 2005; Yamada et al., 2002). 
 
The penochalasins belong to the class of cytochalasins, more precisely to the subgroup of 
chaetoglobosins. Cytochalasins are remarkably cytotoxic metabolites because of their 
effective mode of action, which includes the movement inhibition and cytoplasmic cleavage 
of mammalian cells by inactivation of F-actin. Chaetoglobosins differ from the cytochalasins 
in the presence of a tryptophan moiety rather than phenylalanine.  
 
 
 
 
 
 
 
 
 
The penochalasins A-D are particularly unique as they include a pyrrole moiety in their 
skeleton. They have been isolated from a Penicillium sp. and exhibit cytotoxic activity in the 
low micromolecular range, while those compounds bearing a pyrrole moiety are significantly 
more potent than those without (Iwamoto et al., 2001).  
      
leptosin M 
leptosin A: x=4, y=2 
leptosin B: x=2, y=2 
penochalasin A penochalasin B 
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The potent antileukemic alkaloid sorbicillactone A was isolated from a sponge-derived 
Penicillium chrysogenum by Bringmann and co-workers in 2003. It belongs to the class of 
sorbicillin derivatives and is the first nitrogen-containing natural representative of this 
structural class. It displayed strong cytostatic activity (2.2 µg mL-1) against murine leukemic 
lymphoblast cells (L5178y) whilst showing relatively low toxicity to cervical carcinoma 
HeLa S3 cells and pheochromocytoma PC12 cells (Baker et al., 2007). Other bioactivities 
such as an anti-HIV-activity have been observed as well. The production of sorbicillactone A 
has been increased from 4 mg L-1 up to more than 500 mg L-1 to make it available for clinical 
studies (Bringmann et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
The roridins belong to the group of the mycotoxins trichothecenes. They are well-known plant 
pathogens; however their ability to serve as antitumor substances in humans is subject of 
ongoing discussions (Murakami et al., 2001, and others). 12,13-deoxyroridin E, which has 
been isolated from a marine-derived Myrothecium roridum indeed showed promising 
cytotoxic activity. The derivative roridin E, was even about 80-fold more potent than 12,13-
deoxyroridin E (Namikoshi et al., 2001). These results clearly show that substances that are 
originally known as human pathogens might also be used for clinical use in the future. 
 
12, 13-deoxyroridin E 
sorbicillacton A 
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1.2.3 New sources for cytotoxic secondary metabolites? 
Whether compounds that have been isolated from algae, plants, sponges or corals are possibly 
not only produced by the macroorganisms, but by associated endosymbionts as well, has been 
– and still is – subject of debates (König et al., 2006; Piel et al., 2004). By definition, these 
endosymbionts, mostly fungi and bacteria (including actinomycetes), colonize the living 
internal tissue of their hosts, typically without causing any apparent symptoms of disease 
(Bacon & White, 2000). Endosymbionts usually remain harmless and only become parasitic 
when their host is stressed. The mutual relationship between endosymbiontic microorganisms 
and their hosts often leads to the production of many bioactive metabolites, including known 
as well as new substances, possessing a wide variety of biological activities such as antibiotic, 
antitumor, anti-inflammatory, antioxidant, etc. (Firáková et al., 2007). Currently, more and 
more examples are being published where indeed natural products are produced in one 
species, excreted, and then assimilated by a second species (Simmons et al., 2008). Prominent 
examples for this phenomenon are paclitaxel and podophyllotoxin (see 1.2), or polyketides 
belonging to the pederin family, that have been isolated from endosymbiontic bacteria (Piel et 
al., 2005). Particularly marine invertebrates such as sponges and soft corals are well 
recognized sources for the isolation of endosymbiontic fungi. Strains isolated of these often 
produce unique structures that are likely to be useful for both host and endosymbiont.  
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1.3 Discovery of cytotoxic secondary metabolites 
How was it possible to discover the biological activities for the above-mentioned compounds? 
For a long time the discovery of novel secondary metabolites exhibiting cytotoxic activities 
was based more on coincidence and luck rather than on logical approaches. There are 
countless examples when biological activities were discovered only years after the isolation of 
the substances themselves. On one hand, this is due to the advances that have been made in 
science: many bioassays that are well established today for the investigation of the isolated 
compounds were much less sensitive or not even available at the time the structures have been 
isolated. On the other hand, often a focus on specific activities was not set and compounds 
whose structural features were not familiar to the researcher have been overlooked. 
However, there are urgent needs for the development of novel antitumor drugs. For this 
purpose, the establishment of rational strategies is inevitable to undertake a specific and 
effective screening for cytotoxic active metabolites.  
 
1.3.1 Bioassay-guided isolation 
Bioassay-guided isolation is a widely used rational approach for the discovery of cytotoxic 
compounds. It combines the separation of compounds from a mixture, by using various 
analytical methods, with results obtained from biological testing (Rimando et al., 2001). The 
process begins with testing of the extract to confirm its activity, followed by crude separation 
of the compounds in the matrix and testing of the crude fractions. Further fractionation is 
carried out on the fractions that are found to be active, at a given concentration threshold. The 
inactive fractions are set aside or discarded. The process of fractionation and biological 
testing is repeated until pure compound(s) are obtained. Structural identification of the pure 
compound and, if required, further classification of the bioactivity (e. g. mechanism of action, 
exact target, etc.) is performed afterwards. This methodology precludes overlooking novel 
compounds that remain often undetected in studies where the investigator only identifies 
compounds he is familiar with. Moreover, the possibility of discovering an unknown 
molecular site of action is maximized (Duke et al., 2000). 
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As mentioned above, bioassays play a very important role in today’s natural products 
chemistry research. They must fulfil the following criteria (Sjögren, 2005): 
 
1. Relevant targets 
2. Reliable and reproducible results 
3. Sensitive 
4. Fast 
5. Simple 
6. Standardized detection method, preferably an instrumental method. 
 
All of the parameters listed above should be considered when developing or selecting a 
bioassay. Generally the limiting factor for discovering natural products is the small amount 
available for bioassay and structural analysis from the isolation procedure.  
Applying a high number of bioassays requires considerably more material during the isolation 
procedure than testing towards just one target. As a result, usually a compromise between 
time, target and quantity of isolated material used for the bioassay has to be made.  
 
1.3.2 Established bioassays for discovery of cytotoxic activity 
The bioassays for cytotoxic activity established by Oncotest GmbH are examples for efficient 
test systems fulfilling the requirements as mentioned above (Fig. 1-3-1). The monolayer test 
permits finding the most potent and tumor specific fractions and compounds during screening 
and bioassay-guided isolation. Selected promising compounds can then be subjected to the 
clonogenic assay and, in the case of a positive result, to in vivo studies. 
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Figure 1-3-1:  Testing principle of Oncotest GmbH (taken from www.oncotest.com). 
 
The monolayer-in-vitro-assay determines the capacity of compounds to inhibit growth of 
permanent tumor cell lines. The testing principle is based on an analysis of the viable cell 
number after four days of incubation (Fig. 1-3-2). Tumor derived cell lines are incubated 
together with the test compounds. Proliferation inhibition is then determined by measuring the 
DNA content with propidium iodide or other appropriate markers. Compounds are typically 
tested at different concentrations and evaluated for their potency and tumor selectivity (Fiebig 
et al., 1992; Boven et al., 1992). Most of the cell lines for this assay are established from 
tumor xenografts derived from patients. In vivo counterparts are available for further testing.  
For the screening for cytotoxic compounds, the substances are tested in a six cell-line panel in 
an automated set-up and read-out, which allows a rapid testing of up to 4000 compounds or 
fractions per week. The monolayer-in-vitro-test thus is an eligible tool for bioassay-guided 
isolation of cytotoxic secondary metabolites. 
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Figure 1-3-2:  Principle of the monolayer assay (taken from www.oncotest.com). 
As for a screening for new and bioactive compounds, the automated and fast monolayer assay 
is the appropriate choice. The clonogenic assay would then be the next step for pure 
compounds showing positive results during the screening (Fiebig et al., 2004). It evaluates the 
inhibition capacity of compounds to form three-dimensional colonies which consist of tumor 
cells that possess the potential for anchoring independent growth in semisolid media (Fig. 1-
3-3). Compounds are tested at different concentrations against up to 40 different tumors. 
Evaluation of the activity data from the monolayer assay allows a specific selection of 
suitable tumors.  
 
Figure 1-3-3:  Principle of the clonogenic assay (taken from www.oncotest.com). 
IN-VITRO ANTITUMOR ACTIVITY OF MNEB433F IN HUMAN TUMOR CELL LINES (Monolayer Assay, PI)
────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
TUMOR/  EXP.     CTRL                Distribution of IC70 related to Mean                 IC50        IC70        IC90
PASSAGE NO.      FLUOR.                         log.scaled axis
NO.              UNITS *0.01          *0.1                      *10           *100   ug/ml       ug/ml       ug/ml
─────────────────────────┼──────────────┼────────────Mean─────────────┼──────────────┼──────────────────────────────────
6.220
GXF                      .              .              |        .              .
251L    IF025RT  1439    .              .              ▀▀▀▀▀▀▀▀▀ .              .  12.728      20.775      33.908
.              .              |        .              .
LXF                      .              .              |        .              .
529L    IG025RT  3872    .              .              ▀ .              .   2.335       6.965      21.418
.              .              |        .              .
MAXF                     .              .              |        .              .
401NL   IF026RT  2338    .              .        ▀▀▀▀▀▀▀ .              .   1.306       2.476      56.214
.              .              |        .              .
MEXF                     .              .              |        .              .
462NL   IG026RT  2045    .              .         ▀▀▀▀▀▀ .              .   1.828       3.000      29.999
.              .              |        .              .
RXF                      .              .              |        .              .
486L    IF027RT  2557    .              .           ▀▀▀▀ .              .   1.601       3.665      27.142
.              .              |        .              .
UXF                      .              .              |        .              .
1138L   IG027RT  4421    .              .              ▀▀▀▀▀▀▀ .              .   7.683      14.698      28.115
.              .              |        .              .
────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
Mean                     n=6                         6.220      3.091       6.220      31.268  
────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
CHEMICAL NAME: KN321E10F
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The clonogenic assay is based on human xenografts and combines the advantages of a high 
drug response correlation to the same tumor growing in vivo or in the patient with moderate 
time and running expenditures (Fiebig et al., 2004). Compounds that have been successfully 
tested in the clonogenic assay would then be subjected to in vivo studies as promising 
candidates for future antitumor therapy. 
 
1.4 Heading forward – future prospects for the identification of cytotoxic 
natural products 
The need for new anticancer drugs will not cease in the future. Bearing in mind the relatively 
high toxicity of antitumor drugs in clinical use on one hand and the continuing problem of 
resistance against these compounds on the other, there is a high demand for substances that 
can fulfil the requirements for an activity that acts as broadly as possible while minimizing 
undesired side effects. With the recent developments in analytical chemistry, together with the 
identification and availability of more and more valid molecular targets such as specific 
proteins and receptors or DNA, the possibilities to specifically search for cytotoxic 
compounds increase (Teicher, 2008).  
In the first half of the 20th century, when deeper knowledge about cellular features and DNA 
structure was only beginning to be developed, only very few and unspecific bioassays towards 
cytotoxic activity were established. Nowadays, more sensitive and more diverse bioassays 
exist, corresponding to the many newly characterized targets and key pathways like the 
epidermal growth factor (EGFR) pathway, the insulin-like growth factor (IGF) pathway, or 
microRNAs (Boshoff, 2007), to name just a few. They can be included in bioassay-guided 
isolation of new cytotoxic natural products and might also open the door for the immense 
library of already known natural products to be investigated for a new “career” as antitumor 
agent.  
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2 Scope of the present study 
There is high demand for innovative lead structures in order to develop novel drugs for the 
treatment of cancer and other menacing diseases. Resistance of tumor cells, pathogenic 
bacteria and viruses is steadily increasing and many established drug therapies are not 
effective anymore. Natural products have been shown to possess the potential to be excellent 
lead structures and to serve as a basis for promising therapeutic agents in the area of 
anticancer treatment.  The marine environment is a rather unexplored source in the quest for 
new natural products. The present study was thus devoted to the investigation of cytotoxic 
properties of marine fungal extracts and to the isolation and characterization of the secondary 
metabolites responsible for this activity. It was intended to place special emphasis on 
structurally novel compounds. Furthermore, the characterization of the secondary metabolite 
spectrum of fungi without prominent cytotoxic activity, but with other important biological 
activities, e. g. antimicrobial or human leucocyte elastase inhibitory activity, or with 
interesting chemical properties, was performed. This project thus comprises the following 
tasks: 
 
• Biological and chemical screening of fungal extracts 
• Chemical investigation of interesting fungal strains and bioassay-guided isolation 
• Biological testing of isolated secondary metabolites. 
 
2.1 Biological and chemical screening of fungal extracts 
For screening purposes, selected fungal strains isolated from marine macroorganisms such as 
sponges and algae were cultured in small scale and extracted with EtOH. The crude extracts 
were chemically and biologically evaluated. Biological tests consisted of cytotoxic assays in a 
panel of six cancer cell lines in a monolayer culture, and agar diffusion assays for 
antibacterial, antifungal and antialgal activity. Investigations by 1H-NMR spectroscopy and 
LC-MS measurements were used for the chemical characterization of the fungal extracts. The 
results obtained with these methods were used for the selection of strains which were 
subsequently subjected to detailed chemical and biological analyses.  
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2.2 Chemical investigation of interesting fungal strains and bioassay-
guided isolation 
The selected strains from the screening were cultivated on a large scale and the EtOH extracts 
were subjected to chromatographic methods, mainly HPLC, for the isolation of secondary 
metabolites. It was intended to perform bioassay-guided isolation, using the same cytotoxicity 
test systems as for the screening. Chromatographic steps and cytotoxicity assays were 
repeated until pure compounds were obtained. Structure elucidation of the pure compounds 
was performed by spectroscopic measurements including 1D and 2D NMR techniques and 
mass spectral data. Physico-chemical and physical methods completed the chemical 
characterization of the pure compounds.  
 
2.3 Biological testing of isolated secondary metabolites 
Pure compounds isolated in this study were tested for their cytotoxic activities and, in second 
priority, for antibacterial, antifungal and antialgal activity. Additionally, other bioassays were 
performed when the isolated material was available in sufficient quantities. In these cases, the 
compounds were subjected to further assays to evaluate their ability to inhibit several 
enzymes or antiviral and antiprotozoal activity.  
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3 Materials and methods (general procedures) 
3.1 Origin and taxonomy of fungi 
The strains described in this study were identified by the Centraalbureau voor 
Schimmelcultures, Utrecht, The Netherlands, or by the Leibnitz Insitut für Meeres-
wissenschaften, Kiel, Germany. 
 
Trichoderma saturnisporium (strain 54) was isolated from the sponge Agelas dispar collected 
around the Caribbean island of Dominica. 
 
Beauveria bassiana (strain 321) was isolated from the sponge Myxilla incrustans collected 
around the island of Helgoland (Germany, North Sea). 
 
Alternaria japonica (strain 194) was isolated from an unidentified algae sample collected 
around the Island of Tenerife. 
  
Trichoderma harzianum (strain 714) was isolated from the green alga Chaetomorpha linum 
collected from the waters around Büsum (Germany, North Sea). 
 
Microdiplodia sp. (strain 405) was isolated from the green seaweed Enteromorpha sp. 
collected from the Baltic See waters around the island of Fehmarn (Germany, Baltic Sea). 
 
3.2 Isolation of fungal strains 
All chemically investigated fungal strains described in this study were obtained from fungal 
culture collection of Professor G. M. König (Institute for Pharmaceutical Biology, University 
of Bonn), and were isolated by Ekaterina Eguereva or by the former Ph.D. students Dr. Ulrich 
Höller, Dr. Claudia Osterhage and Dr. Christine Klemke. 
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3.2.1 Isolation from algal material 
After sterilization of the algal material with 70 % ethanol, algal samples were rinsed with 
sterile water and pressed onto agar plates to detect any residual fungal spores on their surface. 
The water used for media was artificial sea water (ASW) containing the following salts: 
[(g L-1): KBr (0.1), NaCl (23.48), MgCl2 x H2O (10.61), CaCl2 x 2H2O (1.47), KCl (0.66), 
SrCl2 x 6H2O (0.04), Na2SO4 (3.92), NaHCO3 (0.19), H3BO3 (0.03)]. Sterilized algae were 
then cut into pieces and placed on agar plates containing isolation medium: biomalt 20 g L-1, 
15 g L-1 agar, 1 L ASW, benzyl penicillin and streptomycin sulphate (250 mg L-1). Fungal 
colonies growing out of the algal tissue were transferred onto a sporulation medium 
consisting of 15 g L-1 agar and 20 g L-1 biomalt extract in artificial sea water (Klemke, 2004). 
 
3.2.2 Isolation from sponge material 
Fungal strains were isolated by inoculating small pieces of the inner tissue of the sponge on 
glucose peptone yeast extract agar at room temperature: glucose 1 g L-1, peptone from Soya 
0.5 g L-1, yeast extract 0.1 g L-1, streptomycin sulphate 250 mg L-1, agar 15 g L-1, 1 L ASW 
(Höller et al., 2000). Fungal colonies growing out of the tissue of the sponge were transferred 
to medium for sporulation (15 g L-1 agar, 20 g L-1 biomalt extract, 1 L ASW). 
 
3.3 Cultivation of fungal strains 
3.3.1 Preparation and maintenance of stock cultures 
The fungal strains were kept in cryogenic polypropylene vials at -80° C on a Mex A medium 
(see 3.9.2). 
 
3.3.2 Pre-cultivation 
For the first pre-cultivation, the fungal strains were inoculated on Petri dishes with BM20 A 
and incubated at 25° C for 4 weeks. 
The second pre-cultivation consisted of inoculation of material taken from the first pre-
cultivation and cultivation of the strain in cultivation tubes containing 10 mL of BM20 A each 
at 25° C for 3 – 4 weeks. 
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3.3.3 Large scale cultivation of the fungal strains 
Fungal strains were cultivated in Fernbach flasks at room temperature for one to three months 
(specific cultivation conditions see chapter 4). The solid media used for the cultivation were 
(a) biomalt agar medium (15 g L-1 biomalt, 15 g L-1 agar and ASW), or (b) malt-yeast agar 
medium (4 g L-1 yeast extract, 10 g L-1 malt extract, 4 g L-1 glucose, 15 g L-1 agar and ASW, 
pH 7.3). For the screening examinations fungal strains were cultivated in Petri dishes for one 
month on three different media: (a) biomalt agar medium, (b) malt-yeast agar medium, or (c) 
czapek agar medium (35 g L-1 czapek solution agar, 15 g L-1 agar and ASW). 
 
3.4 Extraction of fungal biomass 
Cultivation medium and mycelia were homogenized using 
an Ultra Turrax T45. The homogenate was extracted in 
1 L or 2 L round-bottomed flasks with ethyl acetate 
(3 × 300 mL per 300 mL homogenate). The organic 
fractions were combined and the solvent removed under 
reduced pressure at 30° C to yield crude extracts. 
 
3.5 Chromatography 
3.5.1 Thin layer chromatography (TLC) 
Stationary phase for thin layer chromatography was either TLC aluminium sheets silica 
gel 60 F254 (Merck) or TLC aluminium sheets RP-18 F254 (Merck). Standard chromatograms 
of fungal extracts and fractions thereof were prepared at room temperature using 
PE/acetone/EtOAc 50:25:25 or MeOH/H2O 50:50 as mobile phase under saturated conditions. 
The chromatograms were detected using daylight and UV light (254 nm and 366 nm) as well 
as vanillin-H2SO4-reagent (0.5 g vanillin dissolved in a mixture of 85 mL MeOH, 10 mL 
acetic acid and 5 mL H2SO4, TLC plate heated at 95° C after spraying). 
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3.5.2 Open column (CC) and vacuum liquid chromatography (VLC) 
Sorbent for CC was Sephadex LH-20 (0.018-0.111 mm, Pharmacia Biotech AB; size 
exclusion material), using MeOH as eluent. The column was wet packed with MeOH before 
applying the sample solution. 
VLC was carried out using silica gel 60 (0.040-0.063 mm, Merck), silica gel 60 (0.063-
0.200 mm, Merck) or Polygoprep 60 C18 (0.05 mm, Macherey-Nagel; reversed phase). After 
being filled with the appropriate sorbent, columns were compressed under vacuum and 
soaked with PE or MeOH. The columns were equilibrated with the first designated eluent 
before the sample solution was applied. 
 
3.5.3 High performance liquid chromatography (HPLC) 
HPLC was performed on either a Merck-Hitachi system equipped with an L-6200A pump, an 
L-4500A photodiode array detector, a D-6000A interface with D-7000 HSM software and a 
Rheodyne 7725i injection system or a Waters system, controlled by Waters millennium 
software, consisting of a 717 plus auto sampler, 600 controller pump with in-line degasser and 
a 996 photodiode array detector. A third system used for HPLC separations was equipped 
with a Rheodyne 7725i injection system, a Waters 6000A pump, a Knauer differential 
refractometer and a Linseis L 200 E recorder. Columns used were either: 
 
 A: Macherey-Nagel Nucleodur Sphinx C-18 EC (5 µm, 250 × 4.6 mm) 
 B: Phenomenex Luna C-18 (2) 100 Å (5 µm, 250 × 8 mm) 
 C: Knauer Si Eurospher-100 Si (5 µm, 250 × 8 mm) 
 D: Knauer C18 Eurospher-100 (5 µm, 250 × 8 mm) 
 E: Knauer C8 Eurospher-100 (5 µm, 250 × 8 mm) 
 F: Phenomenex Hydro RP-18 (5 µm, 50 × 4.6 mm) 
 G: Waters X-Terra C-18 (5 µm, 250 × 4.6 mm) 
 
Typical flow rates were 1.7 or 2.0 mL min-1 (250 × 8 mm column), or 1.0 mL min-1 (250 × 
4.6 mm column). All solvents, except H2O, were distilled prior to use. The eluents were 
degassed under reduced pressure. 
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3.6 Structure elucidation 
For structure elucidation, one- and two-dimensional NMR techniques were used in 
combination with various mass spectrometric methods. In addition, optical rotations as well as 
the UV and IR spectroscopic properties were determined. The elucidation of the relative and 
absolute stereochemistry of the new compounds was accomplished using the following 
methods: CD spectroscopy, molecular modelling experiments (see 3.6.7) and various NOESY 
experiments. Literature searches were carried out using the MarinLit® database, Antibase® 
and the SciFinder® database. Structures were designated as novel if they could not be found in 
any of the databases. 
 
3.6.1 NMR spectroscopy 
All NMR spectra were recorded either on a Bruker Avance 300 DPX operating at 300 MHz 
(1H) and 75 MHz (13C) or on a Bruker Avance 500 DRX spectrometer operating at 500 MHz 
(1H) and 125 MHz (13C). 
 
NMR spectra were processed using Bruker 1D WIN-NMR, 2D WIN-NMR or XWIN-NMR 
Version 2.6, 3.1 and 3.5 software. Spectra were referenced to residual solvent signals with 
resonances at δH/C 3.35/49.0 for CD3OD, δH/C 7.20/128.0 for C6D6 and δH/C 2.04/29.8 for 
(CD3)2CO. Multiplicity of carbons was deduced by DEPT experiments. Structural 
assignments were based on spectra resulting from one or more of the following NMR 
experiments: 1H, 13C, DEPT135, 1H homonuclear decoupling, 1H-1H COSY, 1H-13C direct 
correlation (HSQC), 1H-13C long-range correlation (HMBC), 1H-1H NOESY, 1H-1H ROESY 
and selective gradient NOE measurements. 
 
3.6.2 Mass spectrometry 
EI, HR-EI and HR-ESI mass spectral measurements were performed by Ms. C. Sondag, 
Department of Chemistry, University of Bonn, Germany, using a Kratos MS 50 and a 
Finnigan MAT 95 spectrometer. 
 
HPLC-ESI-MS measurements were conducted by Dr. A. Krick and E. Eguereva, Institute for 
Pharmaceutical Biology, Bonn, Germany, employing an Agilent 1100 Series HPLC with a 
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Macherey-Nagel Nucleodur C-18 100 (5 µm, 125 mm × 2 mm) and a 2 mmol NH4Ac 
buffered MeOH/H2O gradient system, increasing MeOH from 10 to 100 % over 20 min, 
holding steady for 10 min at 0.25 mL min-1. Separation was monitored by absorption at 
250 nm with a photodiode array detector. The HPLC system was coupled with an API 2000, 
Triple Quadrupole, LC/MS/MS, Applied Biosystems/MDS Sciex with ESI source. For 
injection into the HPLC-ESI-MS system, the samples were solved in MeOH (1 mg mL-1). 
 
3.6.3 UV measurements 
UV spectra were recorded on a Perkin-Elmer Lambda 40 with UV WinLab Version 2.80.03 
software, using 1.0 cm quartz cells. Compounds were measured in methanol. The molar 
absorption coefficient was determined in accordance with the Lambert-Beer-Law: 
 
 
 
A = absorption at peak maximum 
c = concentration 
b = layer thickness of solution 
 
3.6.4 IR spectroscopy 
IR spectra were recorded using a Perkin-Elmer FT-IR Spectrum BX spectrometer interfaced 
with a Specac Golden Gate Diamond ATR system. Analysis and reporting were performed 
with Spectrum v3.01 software. 
 
3.6.5 Optical rotation 
Optical rotation measurements were conducted on a Jasco model DIP-140 polarimeter (1 dm, 
1 cm3 cell) operating at λ=589 nm corresponding to the sodium D line at room temperature. 
Specific optical rotation [α] TD was calculated according to: 
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T: temperature [°C] 
D: sodium D line at λ=589 nm 
c: concentration [g/100 mL] 
d: cell length [dm] 
 
The compounds were dissolved either in MeOH or CHCl3. The rotation angles α were 
determined as an average value based on at least 10 measurements. 
 
3.6.6 CD spectroscopy 
CD spectra were recorded in MeOH or ACN at room temperature using an AVIV 62DS 
spectropolarimeter with the kind help of Prof. Dr. G. Raabe, Institute for Organic Chemistry, 
University of Aachen, Germany. The concentration of the samples was 2.5 × 10-3 mol L-1 and 
the path length was 0.05 cm. A background correction was performed by subtracting the 
spectrum of the neat solvent recorded under identical conditions 
 
3.6.7 Molecular modelling 
The configurations of trichodermanones A-C (see 4.2) were determined by conformation 
search (Boltzmann jump) using the CVFF1.01 force field refined with 500 iterations of smart 
minimization as implemented in the Cerius2 4.0 (MSI) molecular modelling software 
package. Calculations were performed using a Silicon Graphics O2 workstation (Irix 6.5.6). 
 
3.7 In silico screening (PASS) 
In silico screening was carried out via the www interface (http://www.ibmc.msk.ru/PASS/) of 
the PASS (Prediction of Activity Spectra for Substances) software (Poroikov et al., 2001; 
Poroikov et al., 2000; Lagunin et al., 2000). 
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3.8 Biological screening 
3.8.1 Cytotoxicity test against human cancer cell lines 
All cytotoxicity data were provided by Dr. G. Kelter and Dr. A. Maier, Oncotest GmbH, 
Institute for Experimental Oncology, Freiburg, Germany. For screening purposes cytotoxicity 
of fungal extracts against the following six cell lines was evaluated according to Roth and co-
workers (Roth et al., 1999): GXF 251L (gastric), LXFL 529L (large cell lung carcinoma), 
MEXF 462NL (melanoma), RXF 486L (renal), UXF 1138L (uterus carcinoma), 
MAXF 401NL (breast carcinoma). Extracts were tested in concentrations of 10 µg mL-1. 
The cytotoxicity of pure compounds was tested at Oncotest GmbH using 36 human tumor cell 
lines. The origin of the donor xenografts was described by Fiebig and co-workers (Fiebig et 
al., 1992): 
 
 
Bladder BXF 1218L, BXF T24 
CNS CNXF 498NL, CNXF SF268 
Colorectal CXF HCT116, CXF HT29, CXF SW620 
Gastric GXF 251L 
Lung LXF 1121L, LXF 289L, LXF 526L, LXF 529L, LXF 629L, 
LXF H460 
Mammary MAXF 401NL, MAXF MCF7 
Melanoma MEXF 276L, MEXF 394NL, MEXF 462NL, MEXF 541L, 
MEXF 520L 
Ovary OVXF 1619L, OCXF 899L, OVXF OVCAR3 
Pancreas  PAXF 1657L, PAXF PANC1 
Prostate PRXF 22RV1, PRXF DU145, PRXF LNCAP, PRXF PC3M 
Pleuramesothelioma PXF 1752L 
Renal RXF 1781L, RXF 393NL, RXF 486L, RXF 944L, 
RXF UO31 
Uterus body UXF 1138L 
Cell death of ≥  70 % was regarded as active while moderate activity was defined as 50-70 % 
cell death.  
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3.8.2 Agar diffusion assays 
The tests of VLC fractions and pure compounds for antimicrobial activity in vitro were 
performed by E. Neu, Institute for Pharmaceutical Biology, University of Bonn, Germany, 
following the method described by Krohn and co-workers (Schulz et al., 2002). The bacteria 
Bacillus megaterium de Bary (Gram-positive) and Escherichia coli (Migula) Castellani & 
Chambers (Gram-negative), the fungi Eurotium rubrum (formerly E. repens) König, 
Spieckermann & Bremer (Ascomycetes) and Mycotypha microspora Fenner (Zygomycetes) 
were used as test organisms. 
 
Sample solutions contained 1 mg mL-1 per test sample. 50 µL (equivalent to 50 µg) of each 
solution were pipetted onto a sterile antibiotic filter disk (diameter: 9 mm, Schleicher & 
Schuell 2668), which was then placed onto the appropriate agar medium and sprayed with a 
suspension of the test organism. Growth media, preparation of spraying suspensions, and 
conditions of incubation were carried out according to Schulz and co-workers (Schulz et al., 
1995). For tested samples, a growth inhibition zone ≥ 3 mm or a complete inhibition ≥ 1 mm, 
measured from the edge of the filter disk, were regarded as a positive result; growth 
inhibition: growth of the appropriate test organism was significantly inhibited compared to a 
negative control; complete inhibition: no growth at all in the appropriate zone. Benzyl 
penicillin (1 mg mL-1 MeOH), streptomycin (1 mg mL-1 MeOH) and miconazole 
(0.5 mg mL-1 DCM) were used as positive controls. 
 
3.8.3 Antiprotozoal assay 
The antiprotozoal tests were performed by Prof. Dr. R. Brun (Swiss Tropical Institute, Basel, 
Switzerland). Antiplasmodial activity was determined against the K1 strain of Plasmodium 
falciparum, using a modified [3H] hypoxanthine incorporation assay. Briefly, infected human 
erythrocytes were exposed to serial drug dilutions in microtiter plates for 48 h at 37° C in a 
gas mixture with reduced oxygen and elevated CO2. [3H] hypoxanthine was added to each 
well and after further incubation for 24 h the wells were harvested on glass fiber filters and 
counted in a liquid scintillation counter. From the sigmoidal inhibition curve the IC50 value 
was calculated. Chloroquine was used as positive control in each test series. 
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reduction
Resazurin (Alamar Blue®)    
   blue, non-fluorescent 
      Resorufin 
pink, fluorescent 
Activity against Trypanosoma brucei rhodesiense (strain STIB 900), the causative agent of 
African sleeping sickness, was evaluated according to Räz and co-workers, 1997. Parasites 
were grown axenically in culture medium supplemented with horse serum. Following a 3-day 
exposure to test compounds, the viability of tryptomastigote parasites was quantified using 
the dye Almar Blue® by monitoring the reductive environment of living cells (Fig. 3-8-1). 
Fluorescence development was expressed as percentage of the control, and IC50 values were 
calculated. Melarsoprol was included as positive control. 
 
 
 
 
 
 
 
Figure 3-8-1: Alamar Blue® reaction. 
 
Activity against Trypanosoma cruzi, the causative agent of Chagas disease, was determined 
according to Buckner and co-workers, 1996. Briefly, the strain Tulahuen C4 of T. cruzi, 
which had been transfected with the galactosidase lac-Z gene, was cultivated for 4 days on rat 
skeletal myoblasts (5 % CO2, 37° C) in the presence of drug. For measurement of the IC50 the 
substrate chlorophenol red-β-D-galactopyranoside was added. The colour reaction (Fig. 3-8-
2) that developed during the following 2-4 h was quantified photometrically employing an 
ELISA reader. Benznidazole was included in each test series as positive control. 
N
OO OH
O
N
OO OH
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Figure 3-8-2:  Chlorophenol-red reaction. 
 
Evaluation of antileishmanial activity was carried out in mouse peritoneal macrophages. The 
ratio of infection with Leishmania donovani (strain MHOM-ET-67/L82), the causative agent 
of Kala-Azar disease, was determined microscopically after exposure to test compounds, 
incubation and staining with Giemsa. IC50 values were calculated by linear regression. 
Miltefosine was used as positive control.  
Cytotoxicity was evaluated in rat skeletal myoblasts (L6-cells), using podophyllotoxin as 
positive control.  
 
3.8.4 Acetylcholine esterase assay 
Inhibitor experiments with acetylcholine esterase were carried out by the research group of 
Prof. Dr. M. Gütschow (Institute for Pharmaceutical Chemistry, University of Bonn, 
Germany). The general protocol involved a conversion of 5,5´-dithio-bis-2-nitrobenzoic acid 
(DTNB) with thiocholine, originating from the enzymatic degradation of acetylthiocholine, to 
give a product with strong UV absorption at λ = 412 nm (Fig. 3-8-3). Thus, concentration 
shifts of thiocholine were monitored by spectroscopic methods after addition of test 
compounds (25 µM) or extracts (100 µg mL-1). The assay was run in duplicate and repeated at 
least once. Samples that inhibited the enzyme activity greater than 85 % or more relative to a 
negative control were regarded as active. 
 
 
chlorophenol-red chlorophenol red-β-D-galactopyranoside 
                       (yellow) 
 Materials and methods  34
acetylcholine- 
    esterase 
 
 
 
Figure 3-8-3:  Test principle of acetylcholinesterase inhibition assay. 
 
3.8.5 Cysteine protease papain inhibition assay  
Investigations on the inhibitory potential towards papain were performed by the research 
group of Prof. Dr. M. Gütschow (Institute for Pharmaceutical Chemistry, University of Bonn, 
Germany). Using Z-phenylalanyl-arginine-p-nitroanilide (Z-Phe-Arg-pNA) as substrate for 
papain, the enzyme activity was monitored by the formation of free p-nitroaniline. 
Concentration shifts were measured spectrophotometrically at λ = 405 nm after addition of 
bacterial extracts (100 µg mL-1) and expressed as percentage of a negative control. The assay 
was run in duplicate and repeated at least once. 
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3.8.6 Trypsine inhibition assay  
The inhibitory potential towards trypsine was investigated in cooperation with the research 
group of Prof. Dr. M. Gütschow (Institute for Pharmaceutical Chemistry, University of Bonn, 
Germany). Using Succinyl-alanyl-alanyl-propyl-arginine-p-nitroanilide (Suc-Ala-Ala-Pro-
Arg-NHNp) as substrate for trypsine, the enzyme activity was monitored by the formation of 
free p-nitroaniline. Concentration shifts were measured spectrophotometrically at λ = 405 nm 
after addition of bacterial extracts (100 µg mL-1) and expressed as percentage of a negative 
control. The assay was run in duplicate and repeated at least once. 
 
3.8.7 HLE inhibition assay  
Investigations on the inhibitory potential towards human leucocyte elastase were performed 
by the research group of Prof. Dr. M. Gütschow (Institute for Pharmaceutical Chemistry, 
University of Bonn, Germany). Human leukocyte elastase was assayed 
spectrophotometrically at 405 nm at 25° C. Assay buffer was 50 mM sodium phosphate buffer 
(500 mM NaCl, pH 7.8). A stock solution of the chromogenic substrate MeOSuc-Ala-Ala-
Pro-Val-NHNp was prepared in DMSO and diluted with assay buffer. Final concentration of 
DMSO was 1.5 %, the final concentration of the chromogenic substrate MeOSuc-Ala-Ala-
Pro-Val-NHNp was 100 µM, unless stated otherwise. Assays were performed with a final 
HLE concentration of 50 ng mL-1, which corresponded to an initial rate of 0.7 µM min-1, 
when 100 µM of the substrate was used. An inhibitor solution (10 µL) and the substrate 
solution (50 µL) were added to a cuvette that contained the assay buffer (890 µL), and the 
solution was thoroughly mixed. The reaction was initiated by adding the HLE solution 
(50 µL) and was followed over 10 min. IC50 values were calculated from the linear steady-
state turnover of the substrate. The HLE inhibition by the crude extracts was determined in 
the presence of DMSO (0.5 %) and acetonitrile (1 %). 
 
3.8.8 Antiviral assay 
Replication of viruses leads to a complete lysis of host cells, known as cytopathic effect 
(CPE). Antiviral activity of pure compounds was evaluated by Dr. M. Schmidtke (Institute for 
Virology, University of Jena, Germany) in CPE inhibitory assays using crystal violet staining 
on HeLa Ohio cells (human cervix carcinoma; ATCC No. CCL-2) infected with coxsackie 
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virus B3 (CVB3), MDCK cells (Madin-Darby canine kidney; Institute of Influenza viruses, 
St. Petersburg, Russia) infected with influenza virus A and GMK cells (green monkey kidney; 
Schaper and Brümmer, Salzgitter, Germany) infected with herpes simplex virus type 1 (HSV-
1) according to the method described by Schmidtke and co-workers, 2001. 
 
3.8.9 Protein phosphatase assays 
The enzyme assays were conducted in cooperation with Dr. H. Prinz, research group of Prof. 
Dr. H. Waldmann of the Max-Planck-Institute of Molecular Physiology, Dortmund, Germany. 
Pure compounds were tested against the protein phosphatases Cdc25A, PTP1B, MPtpA, 
MPtpB, PTP-SHP2, PTPN2 TC-PTP, VE-PTP, PP1 and VHR using a concentration of 
100 µM L-1 (Brohm et al., 2001). If significant inhibition could be observed, IC50 values were 
determined. 
 
3.9 Chemicals 
3.9.1 Chemicals and solvents 
Acetic acid    Merck (Germany) 
Acetone-d6 99.8 %    Deutero GmbH (Germany) 
Acetonitrile    Merck (Germany) 
Agar-Agar    Fluka (Switzerland) 
Ammonium acetate    Merck (Germany) 
Benzene-d6 99.8 %    Dr. Glaser (Switzerland) 
Benzyl penicillin    Fluka (Switzerland) 
Biomalt extract    Villa Natura GmbH (Germany) 
CaCl2 × 2 H2O    Merck (Germany) 
Chloroform    Merck (Germany) 
Chloroform-d1 99.8 %   Deutero GmbH (Germany) 
meta-Chloroperbenzoic acid (MCPBA)  Fluka (Switzerland) 
CuSO4     Fluka (Switzerland) 
Czapek Solution Agar   Becton Dickinson (MD, USA)  
Dimethylsulfoxide    AppliChem (Germany) 
D-(+)-Glucose    Serva (Germany) 
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Glycerine     Roth (Germany) 
H3BO3     Serva (Germany) 
HCl, 37 %    Merck (Germany) 
KBr     Merck (Germany) 
KCl     Merck (Germany) 
KH2PO4     Merck (Germany) 
Malt-extract    Roth (Germany) 
3-Hydroxy-2-methylbutanoic acid  Prof. Brunet, University of Madrid 
(Spain) 
Methanol Lichrosolv, LC-MS grade  Merck (Germany) 
Methanol-d4 99.8 % D   Deutero GmbH (Germany) 
S-(+)-2-Methylbutyric acid   Fluka (Switzerland) 
(+/-)-2-Methylbutyric acid   Fluka (Switzerland) 
N-methyl-N-(trimethyl-silyl) trifluoroacetamide WGA GmbH (Germany) 
MgCl2 × 6 H2O    Merck (Germany) 
MgSO4 × 7 H2O    Merck (Germany) 
Miconazole    ICN Biomedicals (CA, USA) 
MnCl2 × 4 H2O    Merck (Germany) 
NaCl     Merck (Germany) 
NaHCO3     Merck (Germany) 
NaNO3     Merck (Germany) 
NaOH     Merck (Germany) 
Na2SO4     KMF (Germany) 
Penicillin/Streptomycin   Biomol GmbH (Germany) 
D-(+)-Saccharose    Roth (Germany) 
Sephadex® LH-20    Pharmacia Biotech (Sweden) 
Soyapeptone    Merck (Germany) 
SrCl2 × 6 H2O    Merck (Germany) 
Streptomycin sulphate   Fluka (Switzerland) 
Trimethylsulfonium hydroxide (TMSH)  WGA GmbH (Germany) 
Tween 80     Roth (Germany) 
Yeast extract    Fluka (Switzerland) 
Vanillin     Merck (Germany)  
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All other chemicals were supplied by Merck (Germany), Fluka (Switzerland), Roth 
(Germany) and Sigma-Aldrich (Germany). All other solvents were research grade and 
supplied by Infracor or BASF (Germany). Acetone, CHCl3, CH2Cl2, EtOAc, MeOH and PE 
were distilled prior to use. Water for HPLC was de-ionized using a Millipore system (milli-
Q® academic). 
 
3.9.2 Media 
Mex A: biomalt extract 20 g L-1, yeast extract 0.1 g L-1, glycerin 50 g L-1, 80 % artificial 
seawater, agar-agar 13 g L-1. 
BM20 A: biomalt extract 20 g L-1, 80 % artificial seawater, agar-agar 20 g L-1. 
BM20: biomalt extract 20 g L-1, 80 % artificial seawater. 
BM50: biomalt extract 50 g L-1, 80 % artificial seawater. 
SPG: soyapeptone 10 g L-1, glucose 4 g L-1, KH2PO4 1 g L-1, 80 % artificial seawater. 
YMG: yeast extract 4 g L-1, biomalt extract 1 g L-1, glucose 4 g L-1, 80 % artificial seawater. 
CA: NaNO3 3 g L-1, KH2PO4 1 g L-1, KCl 0.5 g L-1, MgSO4 × 7 H2O 0.01 g L-1, saccharose 
30 g L-1, 80 % artificial seawater. 
 
Artificial seawater (ASW, g L-1) KBr 0.1, NaCl 23.48, MgCl2 × 6 H2O 10.61, CaCl2 × 2 H2O 
1.47, KCl 0.66, SrCl2 × 6 H2O 0.04, Na2SO4 3.92, NaHCO3 0.19 and H3BO3 0.03. 
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4 Results and discussion 
4.1 Screening of fungal extracts for structurally interesting and 
biologically active metabolites 
The focus on the present study was the investigation of marine fungi towards their secondary 
metabolism with an emphasis on structurally novel and biologically active compounds, 
mainly from cytotoxicity bioassays. The fungal strains taken for the cytotoxicity screening 
program of the Institute for Pharmaceutical Biology have been isolated from marine 
macroorganisms such as algae and sponges. For screening purposes the strains were 
cultivated on 500 mL of solid media in Petri dishes. Each strain was cultivated on three 
different media: biomalt agar medium (BMS), malt-yeast agar medium (MYA) and Czapek 
agar medium (CZ). After one month of cultivation, fungal biomass, together with the 
medium, was homogenized and extracted with ethyl acetate. The crude extracts were then 
evaluated by 1H-NMR and LC-MS data and investigated for biological activities. The major 
criterion for selection of the fungal strains was significant cytotoxic activity, tested in a six 
cell line panel at a concentration of 10 µg mL-1. Additionally, agar diffusion tests for 
antimicrobial and antialgal activity were performed. The extracts were tested against the 
bacteria Escherichia coli (E.c.), Bacillus megaterium (B.m.), the fungi Microbotryum 
violaceum (M.v.), Eurotium rubrum (E.r.) and Mycotypha microspora (M.m.) as well as 
towards the alga Chlorella fusca (C.f.).  
 
Of all evaluated fungal strains, five were chosen for further investigation according to the 
results of the antitumor assay and 1H-NMR and LC-MS data as well as, in second priority, 
promising antimicrobial activity (Table 4-1-1). 
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No.1 Taxonomy Medium2 
Crude 
Extract 
(g L-1) NMR MS
Agar diffusion test (growth inhibition in 
mm, conc. 1mg mL-1) Cytotox3
E.c. B.m. M.v. E.r. M.m. C.f. x/ 6 
54 
Trichoderma 
saturnisporium  BMS 0.113 +++ + 0 0 0 0 0 0 1 
54 T. saturnisporium CZ 0.013  -  0 0 0 0 0 0 0 
54 T. saturnisporium MYA 0.417  - + 0 0 0 0 0 0 1&1 
71 Phoma sp.  BMS  0.245 ++ + 0 0 0 0 0 0 0 
71 Phoma sp.  CZ    -   0 0 0 0 0 0 - 
71 Phoma sp.  MYA 0.138  -   0 0 0 0 0 0 6&5 
74 Spicellum roseum BMS 0.461 + + 0 0 0 T5 T11 0 6&6 
74 S. roseum CZ 0.733  -  - 0 0 0 0 0 0 5&4 
74 S. roseum MYA 0.137  -  - 0 0 0 0 0 0 6&6 
96 Microsphaeropsis sp. BMS 0.164 +   0 0 0 0 0 0 6 
96 Microsphaeropsis sp. CZ 0.457  -   0 0 0 0 0 0 6 
96 Microsphaeropsis sp. MYA 0.447  -   0 0 0 0 0 0 6 
193 Paecilomyces  lilacinus  BMS  0.143 +++ ++ 0 0 0 0 0 0 6&4 
193 P. lilacinus CZ 0.187  - - 0 0 0 0 0 0 1 
193 P. lilacinus  MYA 0.082  - - 0 0 0 0 0 0 1 
194 Alternaria japonica  BMS  0.065  -   0 0 0 0 0 0 0 
194 A. japonica  CZ 0.082  -   0 0 0 0 0 0 0 
194 A. japonica  MYA 0.008 ++ + 0 0 0 0 0 0 5 
714 Trichoderma harzianum  BMS 0.060  -  - 0 0 0 0 0 0 1 
714 T. harzianum CZ 0.028  -  - / / / / / / 2 
714 T. harzianum MYA 0.183  -  - 0 0 0 0 0 0 2&3 
738 Acremonium sclerotigenum BMS  0.544   + 0 0 0 0 0 0 6&6 
738 A. sclerotigenum CZ 0.092     0 0 0 0 0 0 4&5 
738 A. sclerotigenum MYA 0.113     0 0 0 0 0 0 0 
741 Phoma macrostoma BMS  0.246 ++ ++ 0 0 0 0 0 0 4&5 
741 P. macrostoma CZ 0.101 + + 0 0 0 0 0 0 0 
741 P. macrostoma  MYA 0.038 + ++ 0 0 0 0 0 0 1 
240 Chaetomium sp. BMS  0.614 +++ +++ 0 T7 0 0 0 0 6 
240 Chaetomium sp. CZ 0.065 + ++ 0 0 0 0 0 0 6 
240 Chaetomium sp. MYA 0.766    0 W2 0 0 0 0 6 
321 Beauveria bassiana BMS  0.226 ++  ++ 0 0 0 0 0 0 6 & 5 
321 B. bassiana  CZ 0.231 +  ++ 0 T3 T6 0 0 0 0 
321 B. bassiana  MYA 0.228 +  ++ 0 0 T4 0 0 0 0 
405 Microdiploida sp. BMS  0.544     0 0 0 0 0 0 2 & 1 
405 Microdiploida sp. CZ 0.042     0 0 0 0 0 0 0 
405 Microdiploida sp. MYA 0.641     0 T3 0 0 0 0 3 
418 Wardomyces anomalus BMS  0.117     0 0 0 0 0 0 4&3 
418 W. anomalus CZ 0.077     0 0 0 0 0 0 2&3 
418 W. anomalus MYA 0.241     0 0 0 0 0 0 4 
1Number refers to the fungal collection (Institute for Pharmaceutical Biology). 
2 BMS, biomalt-agar medium; MYA, malt-yeast medium; CZ, czapek medium. 
3 Number of cell lines showing cytotoxicity in six cell line panel. One or two runs performed, conc. 10 µg mL-1. 
Table 4-1-1:  Overview of the screening results for selected fungal strains. Those chosen for further 
investigation are marked in red. 
 Results  
 
41
Of the marine fungi selected for further investigations during this study, two have been 
isolated from sponges while three are alga-derived. High antitumor activity came from the 
BMS extract of strain 321, a sponge-derived Beauveria bassiana. Together with interesting 
signals in the 1H-NMR and LC-MS spectra, the strain represented a highly interesting 
organism for detailed investigation. Data of the cytotoxicity bioassay was also determining 
for the choice of strain 194, Alternaria japonica isolated from an alga, which was active 
against five cell lines in the cytotoxicity screening. For strain 405 (Microdiploida sp.), 
positive results in both bioassays led to the choice for detailed investigation of this fungus, 
showing cytotoxic activity against three cancer cell lines and antibiotic properties against 
Bacillus megaterium. The MYA-extract of the alga-derived fungus Trichoderma harzianum 
(screening No. 714) also proved to be active in the cytotoxicity bioassay, showing relatively 
high antitumor activity, particularly against the cancer cell line UXF 1138L. Similar data 
came from the sponge-derived fungus Trichoderma saturnisporium (strain 54), which was 
active towards the same uterus cancer cell line and additionally indicated the presence of 
structurally interesting compounds from the 1H-NMR and LC-MS data. This fungus had been 
investigated before by the former Ph.D. student A. Abdel-Lateff (Abdel-Lateff, 2004) and had 
revealed the presence of several known as well as new structures belonging to the class of the 
sorbicillin derivatives. As the stereochemistry of these compounds had remained unclear, 
confirmation of the planar structure and determination of the absolute stereochemistry was 
subjected to further investigation which is part of the present study.  
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4.2 Novel sorbicillin derivatives with an unprecedented carbon 
skeleton from the sponge-derived fungus Trichoderma saturnisporium 
Fungi of the genus Trichoderma are widespread in terrestrial and marine environments, e. g. 
soil and barks. They also live in association with higher plants and sponges. Trichoderma spp. 
are noted for their diverse secondary metabolite chemistry that is not characterized by any 
clear pattern concerning the structural types encountered. To date, more than 500 compounds 
have been reported from fungi belonging to this genus, including the bicyclic dodecanone 
koninginin G (Cutler et al., 1999), the carotane derivatives trichocaranes A–D (Macias et al., 
2000), and the cyclopentenones pentenocins A and B (Matsumoto et al., 1999).  
 
The current secondary metabolite investigation focused on a marine Trichoderma 
saturnisporium, isolated from the Caribbean sponge Agelas dispar. The fungus was cultivated 
on a solid glucose biomalt medium containing artificial sea water (ASW). Successive 
fractionation of the ethyl acetate extract by vacuum liquid chromatography (VLC) and HPLC 
yielded four novel sorbicillinoid polyketide derivatives, compounds 1–4 (Fig. 4-2-1), and the 
monomer rezishanone C (5), a possible product of a Diels-Alder reaction between 
sorbicillinol and a dienophile not related to the sorbicillinoids. Additionally, the known 
sorbicillinoid monomers vertinolide (6) (Trifonov et al., 1982) and epoxisorbicillinol (7) 
(Sperry et al., 1998) and the dimers trichodimerol (8) (Andrade et al., 1992), 
bislongiquinolide (9) (Andrade et al., 1997) and bisvertinol (10) (Trifonov et al., 1986), had 
been isolated; their presence could be confirmed by observation of the corresponding masses 
and several 1H- and 13C-NMR signals in the spectra of several fractions and comparison with 
data previously obtained within our group (Abdel-Lateff, 2004). 
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Figure 4-2-1: Structures of trichodermanones A-D. 
 
Sorbicillines are structurally unusual natural products and were discovered in several species 
of marine and terrestrial fungi, namely Trichoderma spp., Verticillium spp., and Penicillium 
spp (Abe et al., 2000). This class of hexaketides and dimers thereof have been found to 
exhibit a broad range of biological activities including inhibition of lipopolysaccharide-
induced production of tumor necrosis factor alpha (TNF α) in human monocytes, radical 
scavenging and cytotoxicity (Barnes-Seeman & Corey, 1999; Abe et al., 1999; Bringmann et 
al., 2005). 
 
4.2.1 Cultivation, extraction and isolation of secondary metabolites from strain 54 
The sponge Agelas dispar J. was collected in December-January of 1993 by divers using 
SCUBA from the waters around the Caribbean Island of Dominica, Windward Islands. The 
sponge was identified by Dr. R. Desqueroux-Faundez, Musée d’Histoire Naturelle, Geneva, 
Switzerland. The fungus was isolated as described in chapter 3.2.2. The fungal strain was 
identified as Trichoderma saturnisporium by Dr. J. Wiese, Leibnitz Institut für 
Meereswissenschaften, Kiel, Germany. 
In order to increase the amount of the interesting structural types, variations of the culture 
conditions were performed and the fungus was grown in a small scale (0.3 L medium) on six 
different solid media and one liquid medium as shown in table 4-2-1 (Medium 1-7). All solid 
media contained 15 g L-1 agar. After extraction with EtOAc, the 1H-NMR spectra, LC-MS 
data and the amounts of the crude extracts were compared. The addition of glucose to the 
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medium resulted in increased secondary metabolite production, which became apparent by the 
amount of biomass and by the intensified yellow colour of the extract. From the mass spectra, 
the focus was set on the presence of unusual molecular mass values in the region of 300-500 
Da, while the 1H-NMR spectra were evaluated especially with respect to low field resonances 
in the δ 6–8 region. Medium 2 gave the best results regarding a high amount of crude extract 
together with interesting LC-MS data and NMR signals, and therefore was chosen for mass 
cultivation. 
 
    
biomalt glucose ASW crude extract 
(g L-1) 1H-NMR 
Medium 1 solid 50 g L-1 - yes 0.21 ++ 
Medium 2 solid 50 g L-1 15 g L-1 yes 0.33 +++ 
Medium 3 solid 15 g L-1 - yes 0.09 + 
Medium 4 solid 15 g L-1 15 g L-1 yes 0.21 +++ 
Medium 5 solid 15 g L-1 - no 0.17 ++ 
Medium 6 solid 15 g L-1 15 g L-1 no 0.56 ++ 
Medium 7 liquid 15 g L-1 15 g L-1 no 0.08 ++ 
Table 4-2-1: Comparison of medium composition, amounts and results of 1H-NMR data during 
medium optimization attempts for strain 54. 
 
The fungus was thus cultivated at room temperature for two months in 5.75 L (23 Fernbach 
flasks) of solid medium containing 50 g L-1 biomalt, 15 g L-1 glucose, 15 g L-1 agar in 
artificial sea water (ASW). Mycelia and medium were homogenized and the resulting mixture 
was exhaustively extracted with EtOAc and filtered. The filtrate was evaporated to yield 2.5 g 
of a yellowish crude extract. This extract was fractionated by reversed phase vacuum liquid 
chromatography (RP-VLC), employing gradient elution from 10:90 H2O/MeOH to MeOH, to 
yield 9 fractions. According to the differences in composition of the fractions as detected by 
1H-NMR spectroscopy, especially with respect to the resonances in the δ 6–8 region as stated 
above, fractions 4, 5 and 6 seemed promising for further investigation. The three fractions 
were combined and fractionated by NP-VLC, using gradient elution from petroleum ether to 
EtOAc, followed by MeOH, to yield 15 fractions. Fraction 4.6.4 gave a very prominent single 
spot on TLC and was undertaken to further spectroscopic investigation without additional 
purification. The spectral data revealed the compound to be pure 5 (24 mg; Fig. 4-2-2).  
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Figure 4-2-2:  TLC of fractions 4.6.4 to 4.6.10 after detection with vanillin-H2SO4-reagent. Fraction 
4.6.4 is pure 5. 
 
Fraction 4.6.5 yielded 32.0 mg of semi-pure 8. Fractions 4.6.7 and 4.6.8 were combined and 
subjected to RP-18 HPLC (eluent 65:35 MeOH/H2O), to yield seven fractions that were 
further purified by HPLC (eluent 50:25:25 PE/acetone/EtOAc), to yield 14 mg of 2 (tR = 
9 min). 
Compounds 1 (5.2 mg, tR = 37 min) and 3 (11.9 mg, tR = 27 min) were purified from fraction 
4.6.9, after two RP-18 HPLC separations (eluent 60:40 MeOH/H2O for the first and 45:55 
MeOH/H2O for the second HPLC). From fraction 4.6.9 we also isolated semi-pure 6 (tR = 
30.4 min) and semi-pure 9 (tR = 41 min). 
The extract from a second cultivation of the fungus was fractionated by VLC, employing a 
gradient elution from PE to acetone, to yield five fractions (PE/acetone 1:0, 7.5:2.5, 5:5, 
2.5:7.5, 0:1, 200 mL each). According to the low field resonances in the δ 6-8 region of the 
1H-NMR spectral data, fractions 2 and 3 were further investigated. VLC fraction 3 was 
fractionated over NP-Si by VLC employing gradient elution from PE to EtOAc, to yield 11 
fractions (PE/EtOAc 1:0, 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:9, 0:1; 10 mL each). Fraction 
3.4 was then purified by RP-18 HPLC, employing a gradient elution from 9:1 H2O/MeOH to 
MeOH in 45 min, 2 mL min-1, to yield 6 (tR = 32 min, 4 mg), semi-pure 7 (tR = 29 min) and 
semi-pure 9 (tR = 41 min). Fraction 3.6 was purified by RP-18 HPLC, using a gradient of 6:4 
H2O/MeOH to MeOH in 60 min, 2 mL min-1, and yielded four fractions (3.6.4 – 3.6.7; tR = 
25 min, 26 min, 29 min, 35 min, respectively). The first of these fractions was purified using 
Crude 
extract 4.6.4 4.6.5 4.6.6 4.6.7 4.6.8 4.6.9 4.6.10 
Crude 
extract 
Rezishanone C (5) 
 Results  46
RP-HPLC, employing a gradient elution from 65:35 H2O/MeOH to MeOH in 35 min, 
1 mL min-1, to give 10 mg of 3 (tR = 21 min) and 2 mg of 4 (tR = 25 min). HPLC peak 3.6.5 
was purified using RP-18 HPLC (gradient elution 65:35 H2O/MeOH to 20:80 H2O/MeOH in 
35 min, 1 mL min-1) to yield 4 mg of 2 (tR = 22 min), and 1 mg of 3 (tR = 21 min). HPLC peak 
3.6.6 was further purified employing RP-18 HPLC (gradient elution from 7:3 H2O/MeOH to 
3:7 H2O/MeOH in 30 min, 1 mL min-1) to yield 4 mg of 1 (tR = 23.5 min). Fraction 3.6.7 was 
subjected to RP-18 HPLC, using gradient elution from 55:45 H2O/MeOH to MeOH in 60 
min, 2 mL min-1 to yield 10 mg of 3 (tR = 23 min). 
VLC fraction 2 was subjected to normal phase VLC, using a gradient elution from PE to 
EtOAc, to yield five fractions (PE/EtOAc 1:0, 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:9, 0:1, 
200 mL each. Fraction 2.4 was then purified by RP-HPLC, employing gradient elution from 
7:3 H2O/MeOH to MeOH in 50 min, 2 mL min-1, and yielded 1 (tR = 29 min, 2 mg), 2 (tR = 
32 min, 2 mg) and 10 (tR = 44 min, 2 mg). 
 
4.2.2 Structure elucidation 
Accurate mass measurement and 1H- and 13C-NMR analysis of compound 1 showed it to have 
the molecular formula C21H28O8. Its 13C-NMR spectral data allowed five of the eight elements 
of double-bond unsaturation to be attributed to three carbon-carbon double bonds and two 
carbonyl groups (Table 4-2-2); the molecule thus had to be tricyclic. 1H- and 13C-NMR 
spectra showed the presence of two sp3 hybridized methine groups, four sp2 hybridized 
methine groups, three methylene groups, two of them attached to oxygen, one allylic methyl 
group, two methyl groups attached to quaternary carbons, one methoxyl group and eight 
quaternary carbons. The NMR data further enabled all but four hydrogen atoms of 1 to be 
attached to carbons; hence it was evident that the remaining four are present in the molecule 
as hydroxyl functions, a deduction supported by IR data (νmax 3315 cm–1). One of them was 
assigned in the 1H-NMR spectrum to the resonance at δ 14.2, and showing it to probably 
hydrogen-bond to a keto-function. 
 
The planar structure of 1 was deduced by interpretation of its 1H-1H COSY and 1H-13C 
HMBC 2D shift correlated NMR spectral data. Initially, four partial substructures were 
deduced (Fig. 4-2-3).  
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Figure 4-2-3:  Fragments of compound 1 deduced from 1H-1H COSY and 1H-13C HMBC data. 
 
Fragment 1, a sorbyl unit, was elucidated based on a 1H-1H spin system from H3-17 to H-13, 
as well as 1H-13C long range correlations between H-13 and C-12. The chemical shift of C-12 
(δC 167.8) evidenced this carbon to bear a hydroxyl group. Fragment 2 (ring A) was 
characterized by the presence of many quaternary carbons. Heteronuclear long range 
couplings were observed from the resonance of H-6 to those of C-1, C-2, C-4 and C-5, 
between H3-19 and C-4, C-5 and C-6, and between H3-18 and C-2, C-3 and C-4, and 
evidenced these methyl groups to be bonded to C-5 and C-3, respectively. These correlations 
also made clear that C-5 was bound to C-6 and C-4, and C-3 to C-2 and C-4. The chemical 
shifts for C-2 and C-4 in the 13C-NMR spectrum of 1 placed the carbonyl functionalities at 
these positions, while C-1 was part of a carbon-carbon double bond and C-5 hydroxylated. 
From the spectral data it was evident that fragment 3 (ring B) partly overlapped with fragment 
2, i. e. concerning C-3, C-4, C-5 and C-6. Long range C-H correlations between the 
resonances of H-8 and C-3 implied that C-8 is directly bonded to C-3, and C-7 is located next 
to C-6 because of HMBC correlations between H-6 and C-7. According to its characteristic 
chemical shift, C-7 (δC 92.7) must also bear a hydroxyl group. For fragment 4 (ring C), 
proton-proton couplings between H-8 and H-9ax proved that C-8 has to be bonded directly to 
C-9. The latter carbon is linked to C-10 based on HMBC couplings observed between H2-9 
and C-10. Long range correlations between H2-20 and C-9 and C-10 then led to the linkage 
between C-10 and the hydroxy methylene functionality being established. The 13C-NMR 
chemical shifts of C-10 (δ 110.6, s) and C-11 (δ 69.7, t) indicated C-10 to be attached to two 
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and C-11 to one oxygen atom. One of these oxygens connected to C-10 proved to be part of 
the methoxyl group C-21, based on the diagnostic long range correlation observed between 
the resonances of H3-21 and C-10. Subsequently, C-10 and C-11 were concluded to be 
connected via an ether bridge. Finally, long range correlations observed between the 
resonances of H-11 and C-7 showed C-11 to be attached directly to C-7, completing ring C. 
Applying the ACD / Chem Sketch software, the calculated 1H- and 13C-NMR shifts for 
fragments 2, 3 and especially 4 were found to be in good accordance to the experimental data 
and strengthened the suggestion of an ether functionality between C-10 and C-11. Fragments 
1 to 4 were then connected making use of further HMBC correlations. Heteronuclear 
couplings between H-6 and C-12 and between H-13 and C-1 proved that fragment 1 is 
attached to fragment 2 via C-1. Extension of fragment 2 was achieved by connecting C-6 to 
C-7 and C-3 to C-8 (shown in fragment 3), and results in a bridged ring system composed of 
rings A and B. Fragments 3 and 4 must then be linked via C-7 and C-8, since these carbons 
are common to both substructures. Further proof for this structural assignment came from 
long range 1H-1H spin couplings between H2-11 and H-6 and between H3-18 and H2-9. 
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Position δC in ppm δH in ppm, mult., J (Hz) 1H-1H 
COSY-
Correlations 
HMBC-
Correlations 
NOE-
Correlations 
1 112.3 C     
2 199.0 C     
3 64.1 C     
4 210.9 C     
5 74.7 C     
6 49.1 CH 3.38, s  1, 2, 4, 5, 7, 
8, 12 
11eq, 13, 19 
7 92.7 C     
8 50.2 CH 2.56, d, 10.7 9ax 2, 3, 4, 9, 10, 
11 
9eq, 11ax, 18 
9 38.1 CH2 ax: 2.64, dd, 10.7, 13.6 8, 9eq 3, 7, 8, 10 8, 9eq, 20a 
  eq: 1.75, d, 13.6 8, 9ax 3, 7, 8, 10 8, 9ax, 18 
10 110.6 C     
11 69.7 CH2 ax: 4.35, d, 11.8 6, 11eq 7, 8 8, 11eq, 21 
  eq: 3.71, d, 11.8 11ax  6, 11ax 
12 167.8 C     
13 120.4 CH 6.57, d, 15.0 14, 15 1, 12, 14, 15 6, 14, 15, 19 
14 141.4 CH 7.22, dd, 10.9, 15.0 13, 15, 16, 17 12, 16 13, 15, 16 
15 132.1 CH 6.38, dd, 10.9, 15.0 13, 14, 16 16, 17 13, 14, 16, 17 
16 138.7 CH 6.18, dq, 15.0, 6.8 13, 15, 17 14, 15, 17 14, 17 
17 18.8 CH3 1.80, d, 6.8 13, 15, 16 15, 16 15, 16 
18 10.9 CH3 1.10, s 8, 9ax 2, 3, 4, 8 8, 9ax 
19 27.0 CH3 1.14, s  4, 5, 6 6, 13 
20 62.7 CH2 a: 3.82, d, 10.9 20b 9, 10 9eq, 11eq, 20b, 
21 
  b: 3.40, d, 10.9 20a  9eq, 11eq, 20a 
21 48.8 CH3 2.98, s  10 20a, 20b, 11ax 
12-OH  14.20, s    
Table 4-2-2: NMR-spectral data of 1 measured in [D6]acetone at 300 and 500 MHz. 
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2D NOESY and selective gradient NOE data, energy-minimized 3D models and proton 
coupling constant analysis and calculations, as well as CD measurements were used to assign 
the absolute configuration. First the sorbicillin part of the molecule was investigated. The 
bridged ring system consisting of rings A and B is only possible if H-6 and CH3-18 are 
disposed equatorially. NOE enhancements of H-13 and H-6 were observed by irradiation of 
H3-19, showing the C-19 methyl group to be oriented towards the sorbyl side chain. With this 
information, the relative configuration of this part of the molecule was designated as 3R*, 
5S*, 6R*. A CD spectrum of 1 gave proof for the 3R, 5S, 6R absolute configuration of the 
molecule (Fig. 4-2-4). Characteristic Cotton effects with a minimum at 295 nm and a 
maximum at 335 nm were observed that corresponded well with those reported for 
rezishanone C (294 and 335 nm, Maskey et al., 2005), which contains a similar sorbicillin-
substructure to the one reported here. 
 
 Figure 4-2-4: CD spectrum of compound 1 (MeOH, conc. 1.0 × 10-3 mol L-1). 
 
Selective NOE experiments also proved to be helpful for deducing the configuration of the 
non-sorbicillin part of 1. NOE enhancements observed for H-8 and of CH3-21 upon 
irradiation of the H-11ax resonance (δ 4.35) indicated the methoxyl group and H-8 to have 
axial orientation, and to be located on the same side of the molecule. Consequently, H-11 
(δ 3.71) must have equatorial orientation, a finding that also explains the enhancement of H-6 
by irradiation of H-11eq (δ 3.71). Ring C thus adopts a chair conformation.  
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Still missing at this point was information concerning the relative configuration at C-7. 
Furthermore, the relative configuration of ring A (C-3, C-5 and C-6) could not yet be related 
to that of ring C (C-7, C-8, C-10). NOE experiments were not useful in this case due to the 
quaternary nature of C-7. It was suspected however that the conformation of ring C and thus 
1H-1H coupling constants were dependent on the configuration at C-7. The magnitude of 
proton-proton coupling constants deduced from 1H-NMR experiments were thus considered 
and compared with those obtained from molecular modelling calculations. It was clear from 
the large coupling constant measured for J8/9ax (10.7 Hz) that, according to the Karplus 
equation (Karplus, 1959; Karplus, 1963; Haasnot et al., 1980), these two protons must have a 
torsion angle of close to 180°. The absence of 1H-1H couplings between H-8 and H-9eq 
indicated the dihedral angle between these two protons to be close to 90°. Four models were 
calculated for compound 1 taking into account all possible configurations at C-7, C-8 and C-
10; i. e. 7R, 8R, 10S; 7S, 8R, 10S; 7S, 8S, 10R and 7R, 8S, 10R, with configurations at C-3, C-
5 and C-6 taken as R, S and R, respectively (Fig. 4-2-5).  
 
Model #4, having 7R, 8S, 10R configuration, was considered not appropriate, as ring C does 
not have the required chair conformation. When comparing the remaining models that all 
displayed ring C in a chair conformation, a significant difference was noted concerning the 
size of the dihedral angles between H-8 and H-9ax/H-9eq. These torsion angles were calculated 
for the energy minimized structures #1 to #3 and used in the Karplus equation to calculate the 
expected 1H coupling constants. 
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Figure 4-2-5:  Minimum energy conformation of epimers of 1 (minimization program see 3.6.7). 
 
As shown in table 4-2-3, the calculated coupling constants for the minimized 7R, 8R, 10S 
epimer corresponded best with the actual NMR values and thus led to the conclusion that 1 
possesses a trans-junction between the sorbicillin part and the non-sorbicillin part of the 
molecule, with the hydroxyl group at C-7 having α orientation. Based on this evidence, the 
absolute configuration of 1 is proposed as 3R, 5S, 6R, 7R, 8R, 10S. For 1, the trivial name 
trichodermanone A is proposed.  
 
Minimum energy conformation of the 
7R, 8R epimer of 1 (model #1)   
Minimum energy conformation of the 
7S, 8R epimer of 1 (model #2)  
Minimum energy conformation of the 
7S, 8S epimer of 1 (model #3)  
Minimum energy conformation of the 
7R, 8S epimer of 1 (model #4)  
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 Torsion angle  Coupling 
constant 
calculated (Hz) 
Compound  Coupling 
constant 
measured (Hz) 
Model #1[a] H-8/H-9eq   78.6° 1.2 1 H-8/H-9eq 0.0 
 H-8/H-9ax 171.4° 12.1  H-8/H-9ax 10.7 
Model #2[a] H-8/H-9eq   29.3° 8.0 2 H-8/H-9eq 7.3 
 H-8/H-9ax 145.8° 9.1  H-8/H-9ax 9.9 
Model #3[a] H-8/H-9eq   62.0° 2.7 3 H-8/H-9eq 7.0 
 H-8/H-9ax 179.8° 12.4  H-8/H-9ax 9.9 
Model #4[a] H-8/H-9eq   45.3° 5.3    
 H-8/H-9ax 160.8° 11.3    
[a] Implied configuration for all models is 3R, 5S, 6R 
Table 4-2-3:  Calculated 1H-1H coupling constants for models #1–4 and measured coupling constants 
for compounds 1 – 3. 
 
Mass spectral analysis of 2 showed it to have the same molecular formula as 1. Analysis of its 
NMR data, in particular the 1H-1H COSY and 1H-13C HMBC spectral data, revealed 2 and 1 
to have identical planar structures meaning the two molecules must differ in configuration at 
one or more of their chiral centers (Table 4-2-4). NOE correlations for 2 were observed 
between H-6, H-13 and H3-19 as in 1. A CD spectrum of 2 showed it to be almost congruent 
to that measured for 1, proving the configuration in the sorbicillin part of the molecule to be 
the same as for 1. Ring C of 2 must also have a chair conformation due to mutual NOE 
enhancements of H3-21 and H-8 with H2-11, respectively. Irradiation of H-8 caused 
enhancements of both H-9ax (δ 1.69) and H-9eq (δ 2.17), indicating that the torsion angles 
between H-8 and the protons at C-9 are different from those in 1. The proton coupling 
constants measured for J8/9ax (9.9 Hz) and J8/9eq (7.3 Hz) confirmed this deduction. With this 
information in hand the measured 1H-1H coupling constants of 2 were compared to those 
calculated for models #1 to #3 (Table 4-2-3). The actual coupling constants obtained by 
experimental measurement were almost identical to those calculated for model #2, that has a 
cis-junction of rings B and C, and C-7 and C-8 having S and R absolute configurations, 
respectively. For 2 the absolute configuration of 3R, 5S, 6R, 7S, 8R, 10S, and the trivial name 
trichodermanone B are proposed.  
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Position δC in ppm δH in ppm, mult., J 
(Hz) 
1H-1H 
COSY-
Correlations 
HMBC-
Correlations 
NOE-
Correlations 
1 111.5 C     
2 200.2 C     
3   64.5 C     
4 210.9 C     
5   74.7 C     
6   49.1 CH 3.51, s  1, 2, 4, 5, 7, 8, 12 11, 13, 19 
7   90.3 C     
8   49.7 CH 2.56, dd, 7.3, 9.9  9eq, 9ax 2, 3, 4, 9, 11, 18 9eq, 9ax, 11, 18 
9   40.9 CH2 ax: 2.17, dd, 9.9, 13.9 8, 9eq 3, 8, 10, 20 8, 9eq, 18 
  eq: 1.69, dd, 7.3, 13.9 8, 9ax 3, 7, 8, 10 8, 9ax, 18 
10 111.0 C     
11   68.4 CH2 3.91, br m 20a 6, 7 6, 8, 21 
12 168.9 C     
13 120.0 CH 6.44, d, 15.0 14, 15, 16 12, 15 6, 14, 15, 16, 
19 
14 142.1 CH 7.25, dd, 11.0, 15.0 13, 15, 16, 17 12, 15, 16 16 
15 132.0 CH 6.39, dd, 11.0, 15.0 13, 14, 16, 17 16, 17 13, 17 
16 139.5 CH 6.23, dq, 15.0, 7.0 13, 15, 17 14, 15, 17 14 
17   18.8 CH3 1.86, d, 7.0 13, 15, 16 13, 15, 16 15, 16 
18   11.8 CH3 1.08, s 8, 9eq 2, 3, 4, 8 8, 9eq 
19   26.5 CH3 1.14, s  4, 5, 6 6, 11, 13 
20   62.2 CH2 a: 3.85, d, 11.0 20b 10 9eq, 20b, 21 
  b: 3.01, d, 11.0 20a  20a, 21 
21   48.9 CH3 3.20, s   11, 20b 
Table 4-2-4:  NMR-spectral data of 2 measured in [D6]acetone at 300 and 500 MHz. 
 
The molecular formula and NMR data of 3 revealed it to have the same planar structure as 2 
except for the functionality at C-10, being -OCH3 in 2 and -OH in 3. The 13C-NMR data for 
the two compounds were almost identical with the exception of the resonance frequencies 
associated with C-10 and C-20 (Table 4-2-5).  
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Position δC in ppm δH in ppm, mult., J 
(Hz) 
1H-1H 
COSY-
Correlations 
HMBC-
Correlations 
NOE-Correlations 
1 111.6 C     
2 200.0 C     
3   64.4 C     
4 211.0 C     
5   74.7 C     
6   49.6 CH 3.37, s 19 1, 2, 4, 5, 7, 8, 
12 
11ax, 11eq, 13, 19 
7   90.3 C     
8   49.9 CH 2.71, dd, 7.0, 9.9 9eq, 9ax 2, 3, 4, 9, 11, 
18, 20 
9eq, 11ax, 11eq, 18 
9   40.3 CH2 ax: 2.17, dd, 9.9, 14.1 8, 9eq 3, 7, 8, 10 8, 9eq 
  eq: 1.74, dd, 7.0, 14.1 8, 9ax 3, 6, 8, 10 9ax, 20 
10 107.5 C     
11   68.2 CH2 ax: 4.28, d, 11.7 11eq 6 8, 11eq 
  eq: 3.76, d, 11.7 11ax 6, 7, 8 6, 11ax 
12 168.8 C     
13 120.1 CH 6.45, d, 15.0 14, 15, 16, 17 12, 15 6, 15, 16 
14 142.1 CH 7.24, dd, 10.6, 15.0 13, 15 12, 16 16 
15 132.0 CH 6.36, dd, 10.6, 15.0 14, 16  13, 14, 16, 17 
16 139.3 CH 6.25, dq, 15.0, 6.5 13, 15, 17 14, 17 14, 17 
17   18.8 CH3 1.85, d, 6.5 15, 16 15, 16 15, 16 
18   11.0 CH3 1.09, s  2, 4, 8 8, 9ax 
19   26.9 CH3 1.14, s 6 2, 4, 5, 6 6 
20   67.4 CH2 3.29, s  10  
Table 4-2-5:  NMR-spectral data of 3 measured in [D6]acetone at 300 and 500 MHz. 
 
The configuration of the sorbicillin part of the molecule was solved by taking the mutual 
NOE correlations between H-6, H-13 and H-19 into account, and by comparison of the CD 
spectra of 3 with those of 1 and 2, and found to be as shown in 3. The mutual NOE 
correlations observed between H-8 and H-11ax indicated ring C to have a chair conformation, 
similar to that found in 1 and 2. Calculation of the 1H-1H coupling constants for J8/9ax and 
J8/9eq yielded values comparable to those measured for model #2, showing that 3 has a cis 
junction between rings B and C, leading to the absolute configuration of 3 being best 
described as 3R, 5S, 6R, 7S, 8R, 10S. The trivial name trichodermanone C is proposed for 3. 
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Mass spectral analysis of 4 showed it to have the molecular formula C19H20O7. Extensive 
comparison of 1H, 13C, 1H-1H COSY, and 1H-13C HMBC NMR spectral data of 1 and 2 with 
those of 4 showed that the data were in good agreement concerning the sorbyl unit, and rings 
A and B (Table 4-2-6). Differences between the compounds were, however, evident from the 
spectral data associated with ring C. From 1H-1H COSY correlations observed between H-8 
and H-9, and the HMBC couplings observed between H-9 and C-8, it was clear that C-9 had 
to be attached to C-8. HMBC couplings between H-9 and C-10 and C-11 enabled the C-C 
bond from C-9 to C-10 to be established. Linkage between C-7 and C-11 via an oxygen and 
the completion of ring C was probable taking into account the 13C-NMR shift of C-7 (δ 80.9, 
d), which clearly differs from the equivalent atom in 2 (δ 90.3, s). Comparison of the NOESY 
correlations and the CD spectra of 2 and 4 showed the configuration for this pair of molecules 
to be the same for the stereogenic centers C-3, C-5 and C-6; 3R, 5S, 6R. The large 1H-1H 
NMR coupling constants associated with H-8 and H-7 (JH7, H8 = 10.6 Hz) showed these 
protons to have either a dihedral angle of about 180° or close to 0°; mutual NOESY 
correlations between H-8 and H-7 revealed the angle to be close to 0° meaning the junction 
between rings B and C had to be cis. In order to obtain information on the absolute 
configurations at C-7 and C-8, molecular modelling experiments with the two possible 
isomers (7S, 8R and 7R, 8S) were performed. The two models unfortunately did not show 
significant differences in the torsion angles for H-7 and H-8 and so the absolute configuration 
of 4 remains unresolved. 
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Position δC in ppm δH in ppm, mult., J 
(Hz) 
1H-1H 
COSY-
Correlations 
HMBC-
Correlations 
NOE-Correlations 
1 107.8 C     
2 198.9 C     
3   64.7 C     
4 202.3 C     
5   74.5 C     
6   47.6 CH 3.74, d, 3.7 7 1, 2, 4, 5, 7, 8, 12 13, 19 
7   80.9 CH 5.57, dd, 3.7, 10.6 6, 8 1, 3  
8   53.0 CH 3.58, dd, 2.9, 10.6 7, 9 2, 3, 4, 6, 9 9, 18 
9 109.6 CH 5.75, d, 2.9 8 7, 8, 10, 11 8, 18 
10 151.7 C     
11 161.0 C     
12 170.9 C     
13 120.2 CH 6.55, d, 15.0 14, 15, 16 1, 12, 15 6, 15, 17 
14 143.4 CH 7.29, dd, 11.0, 15.0 13, 15 12, 16 16 
15 132.6 CH 6.44 dd, 11.0, 15.0 14, 16 16, 17 13, 17 
16 140.1 CH 6.26, dq, 15.0, 7.0 13, 15, 17 15, 17 14, 17 
17   19.2 CH3 1.88, d, 7.0 15, 16 15, 16 15 
18   10.6 CH3 1.19, s  2, 3, 4, 8 8, 9 
19   23.9 CH3 1.25, s  4, 5, 6 6 
Table 4-2-6:  NMR-spectral data of 4 measured in [D6]acetone at 300 and 500 MHz. 
 
The structure of compound 5 was elucidated by 1D and 2D NMR spectroscopy, LC-MS data 
and comparison with literature data. Rezishanone C has only been known for a few years. As 
the presumed precursor for the formation of the structure, ethyl vinyl ether has never been 
isolated as a natural product so far, 5 is discussed to be an artefact which is formed during the 
isolation process (Maskey et al., 2005). Rezishanone is described to exhibit weak antibiotic 
activity against Staphylococcus aureus and Bacillus subtilis. 
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Investigation of NMR data and mass spectroscopy of the VLC fractions and comparison with 
previous work from our group also revealed the presence of the known compounds 6-10, 
which have been isolated by the former Ph.D. student A. Abdel-Lateff (Fig. 4-2-6; Abdel-
Lateff, 2004).  
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Figure 4-2-6:  Secondary metabolites produced by Trichoderma saturnisporium. 
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Vertinolide (6) is the only compound isolated from T. saturnisporium that does not show the 
typical sorbicillin substructure, but possesses a cyclopentanone instead of the cyclohexanone 
moiety. The structure has been deduced by X-ray analysis by Trifonov and co-workers 
(Trifonov et al., 1982). 
Epoxisorbicillinol (7) was first isolated in 1998 from a sponge-derived Trichoderma species 
(Sperry et al., 1998) and until today represents the only sorbicillin derivative possessing an 
epoxide function. No biological activities have been observed to date. 
Trichodimerol (8) is probably the best investigated compound belonging to the sorbicillinoids. 
It was isolated for the first time by Andrade and co-workers from a terrestrial Trichoderma 
longibrachiatum (Andrade et al., 1992). Structure confirmation via the crystallographic 
analysis was published in 1995 (Gao et al., 1995). Trichodermanone has demonstrated 
inhibition of lipopolysaccharide (LPS)-stimulated tumor necrosis factor-alpha secretion in 
various in vitro macrophage models (human and murine) including primary and tumor cell 
lines (Mazzucco & Warr, 1996). 
Compound 9 (bislongiquinolide), which has been isolated from Trichoderma longibrachiatum 
as well, (Andrade et al., 1997) is a bisorbicillinoid exhibiting antioxidant properties, which is 
very common among sorbicillin derivatives. 
Bisvertinol (10) also represents the group of the bisorbicillinoids, characterized by the 
presence of two sorbicillin substructures within the molecule. It was first obtained from 
Verticillium intertextum as a yellow amorphous powder (Trifonov et al., 1986). As for other 
sorbicillinoids and bisorbicillinoids, a weak radical scavenging activity has been observed in a 
DPPH assay. 
 
Trichodermanone A (1): 
 C21H28O8 (408.18) 
Yellowish viscous oil (5.2 mg); [α]22D = + 203.0 (MeOH, c 0.24).  
1H- and 13C-NMR: see table 4-2-2;  
UV (MeOH) λmax (log ε): 360 (4.6), 248 (4.2), 203 (4.2) nm;  
CD (MeOH) ∆ε= 335 (+ 1.990), 293 (- 1.945);  
IR (film): ν = 3315, 2920, 2851, 1732, 1630, 1602, 1565, 1455, 1381 cm-1;  
EIMS m/z (% rel int), 408 (10) [M]˙+, 376 (100), 101 (80), 95 (40), 59 (90);  
Cytotoxicity assay: not active; 
Agar diffusion assay: not active; 
Acetylcholine esterase assay: not active; 
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Trypsine inhibition assay: not active; 
Phosphatase assays: not active; 
 
 
Trichodermanone B (2):  
C21H28O8 (408.18) 
Yellowish viscous oil (14 mg); [α]22D = +  251.0 (MeOH, c 0.2).  
1H- and 13C-NMR: see table 4-2-4;  
UV (MeOH) λmax (log ε): 358 (4.7), 248 (4.2), 202 (4.4) nm;  
CD (MeOH) ∆ε = 348 (+5.436), 310 (-6.950);  
IR (film) ν = 3393, 2938, 1733, 1630, 1600, 1561, 1383 cm-1;  
EIMS m/z (% rel int), 408 (22) [M]˙+, 376 (80), 359 (50), 305 (20), 287 (28), 101 (82), 95 
(70), 59 (76); 
Cytotoxicity assay: not active; 
Agar diffusion assay: not active; 
Acetylcholine esterase assay: not active; 
Trypsine inhibition assay: not active; 
Phosphatase assays: not active; 
 
 
Trichodermanone C (3):  
C20H26O8 (394.16) 
Yellowish viscous oil (11.9 mg); [α]22D = + 265.7 (MeOH, c 0.5).  
1H- and 13C-NMR: see table 4-2-5;  
UV (MeOH) λmax (log ε): 360 (4.3), 248 (3.8) nm;  
CD (MeOH) ∆ε = 333 (+ 11.678), 297 (- 10.631);  
IR (film) ν = 3330, 2937, 1731, 1627, 1597, 1556, 1380 cm-1;  
EIMS m/z (% rel int), 394 (20) [M]˙+, 376 (100), 305 (22), 287 (20), 101 (37), 95 (65), 59 
(37); 
Cytotoxicity assay: not active; 
Agar diffusion assay: not active; 
Acetylcholine esterase assay: not active; 
Trypsine inhibition assay: not active; 
Phosphatase assays: not active; 
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Trichodermanone D (4):  
C19H20O7 (360.13) 
Yellowish viscous oil (2 mg); [α]22D = + 51.5 (MeOH, c 0.08).  
1H- and 13C-NMR: see table 4-2-6;  
UV (MeOH) λmax (log ε) 360 (4.3), 250 (4.2), 204 (4.1) nm;  
IR (film) ν = 3383, 2923, 2359, 1729, 1599, 1404 cm-1;  
ESIMS: positive ion m/z 361 [M + H]+, negative ion m/z 359 [M – H]+;  
 
 
Rezishanone C (5): 
C18H24O5 (320.38) 
Yellow amorphous powder (24 mg); 
1H-NMR [300 MHz, (CD3)2CO]: δ = 1.06 (3H, dd, J = 6.9, 8.5 Hz, H3-10), 1.15 (3H, s, H3-
17), 1.19 (3H, s, H3-18), 1.64 (1H, m, H-2a), 1.85 (3H, d, J = 6.9 Hz, H3-16), 2.87 (1H, d, J = 
8.1 Hz, H-2b), 3.24 (1H, s, H-3), 3.34 (1H, m, H-9a), 3.56 (1H, m, H-9b), 3.62 (1H, t, J = 8.1 
Hz, H-1), 6.23 (1H, m, J = 6.9, 14.5 Hz, H-15), 6.39 (1H, dd, J = 10.9, 14.5 Hz, H-14), 6.52 
(1H, d, J = 14.9 Hz, H-12), 7.24 (1H, dd, J = 10.9, 14.9 Hz, H-13);  
13C-NMR [75.5 MHz, (CD3)2CO]: δ = 9.5 (q, C-18), 15.4 (q, C-10), 18.8 (q, C-16), 24.0 (q, 
C-17), 31.1 (t, C-2), 40.9 (d, C-3), 65.6 (t, C-9), 68.0 (s, C-6), 74.2 (s, C-8), 79.1 (d, C-1), 
112.1 (s, C-4), 119.7 (d, C-12), 132.0 (d, C-14), 139.1 (d, C-15), 142.0 (d, C-13), 166.9 (s, C-
11), 198.0 (s, C-5), 209.4 (s, C-7);  
ESIMS: positive ion m/z 321 [M + H]+, negative ion m/z 319 [M - H]+; 
Agar diffusion assay: not active; 
Literature: Maskey et al., 2005 
 
Compounds 6-10 have been described by Abdel-Lateff (Abdel-Lateff, 2004). 
 
4.2.3 In silico screening of the trichodermanones (1-4) 
In order to identify the possible biological activity of the trichodermanones (1-4), the 
compounds were investigated in an in silico screening approach using the PASS software 
(Poroikov et al., 2000; Poroikov et al., 2001). The results indicated that the probability was 
highest for respiratory analeptic and TNF α inhibitory activity (respiratory analeptic: 
Pa 0.761, Pi 0.005; TNF α: Pa 0.752, Pi 0.004; values for compound 2). 
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4.2.4 Biological testing of the trichodermanones (1-4) 
Compounds 1–3 were tested in variety of bioassays including agar diffusion tests for 
antimicrobial properties, tests for antiparasitic and cytotoxic activity, phosphatase inhibiting 
activity, acetylcholine esterase inhibition and trypsin inhibition. In each case no activity was 
observed for the tested compound. Due to the small amount of 4 obtained during isolation it 
could not be tested in any of the assays. 
 
4.2.5 Discussion 
Natural products belonging to the sorbicillin class are hexaketide-derived metabolites. All of 
these compounds are composed of a cyclohexanone ring to which a sorbyl, i. e. hexa-2,4 dien-
one, chain is attached. Structural variations within this structural class concern the substitution 
of the cyclohexanone ring, which is often further methylated and hydroxylated. The sorbyl 
side chain, however, in most cases remains unchanged with exception of a few 2,3-
dihydrosorbyl-derivatives (Maskey et al., 2005). More than 30 different sorbicillin monomers 
have been found to date. For the recently published rezishanones it is postulated that they 
originate from sorbicillinol and butylvinyl or ethylvinyl ethers attached to sorbicillinol via a 
Diels-Alder reaction. The only known nitrogen-containing sorbicillinoids are the anti-cancer 
agents sorbicillactone A and B, whose biosynthesis also involves sorbicillinol, the amino acid 
alanine and presumably a fumaryl-related C4 unit (Bringmann et al., 2005). Sorbicillinol itself 
was also shown to be the common precursor for many dimeric sorbicillin derivatives giving 
rise to a high structural diversity within this group of natural products (Trifonov et al., 1982). 
The dimers are biosynthetically generated from sorbicillinol through two ways of 
dimerization, i. e. Diels-Alder cycloaddition, as in the case of bisorbicillinol (Nicolaou et al., 
1999), and Michael addition, as suggested for trichodimerol (Nicolaou et al., 2000). 
 
Compounds 1–4, even though sharing the basic sorbicillin part of their structures with that of 
other sorbicillinoids, possess an unprecedented tricyclic ring system. They are unique with 
regard to ring C, which may arise biosynthetically by combining a non-sorbicillinoid 
polyketide with the hexaketide-derived sorbicillinol. A biosynthetic pathway proposed for 
compounds 1–4 is shown in figure 4-2-7. Our proposal is similar to that of Trifonov and co-
workers (Trifoniv et al., 1986) for the bisvertinols concerning the first steps of biosynthesis 
up to the formation of sorbicillinol: In their concept all known sorbicillinoid structures derive 
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from 2,4-dimethyldodecyl units yielding sorbicillin, an assumption confirmed by Abe and co-
workers via biosynthetic studies with labelled acetate units (Abe et al., 2001). According to 
Trifonov and co-workers sorbicillin undergoes an epoxidation, a process also proposed as a 
key step in the biosynthesis of penicillic acid from orsellinic acid (Al-Rawi et al., 1974). 
Opening of the epoxide ring would then lead to the quinol sorbicillinol. It is probable that 
compounds 1–4 were produced from sorbicillinol via a Diels-Alder cycloaddition of another 
polyketide, followed by cyclization and hydroxylation to give compounds 1–3, or oxidation 
and decarboxylation to yield compound 4 (Fig. 4-2-7). This combination of two polyketide 
precursors for the formation of secondary metabolites is especially exciting, as this is a very 
rare case in nature. 
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Figure 4-2-7:  Proposed biosynthesis of the trichodermanones. 
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Involvement of biological Diels-Alder reactions is presumed in the biosynthesis of a variety 
of secondary metabolites since many years (Katayama et al., 2008; and other). Among the 
candidates for such a biogenetic path are the alkaloid presecamines (Bazan et al., 1978), the 
terpenoid heliocides (Stipanovic et al., 1977), or the solanapyrones (Oikawa, 1989).  
 
For a few years, there have been discussions arising about the presence of enzymes or other 
cellular features that catalyze Diels-Alder cycloadditions in microorganisms, namely the 
Diels-Alderases (Katayama et al., 2008; Oikawa, 2005). Indeed, the function and catalytic 
mechanism of natural Diels-Alderases would be of great interest due to the diversity of 
molecular skeletons in natural Diels-Alder adducts. The discovery of several ribozyme Diels-
Alderases catalyzing such reactions has been published in the last years (Keiper et al., 2004). 
It is thus possible that such an enzyme is involved in the biosynthesis of the trichodermanones 
as well. However, the possibility cannot be excluded that an enantioselective enzymatic 
activation of the precursor molecule sorbicillinol leads to spontaneous cyclization and 
forming of the compounds. Attempts isolating catalytic enzymes involved in the [4+2] 
addition of the second polyketide to sorbicillinol should thus be performed in order to obtain 
more evidence of the biosynthetic pathway of the trichodermanones. 
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4.3 Beauveria bassiana (strain 321) and Microdiplodia sp. (strain 405): 
Cytotoxic and HLE-inhibitory tetramic acid derivatives from marine-
derived fungi  
Tetramic acid derivatives are an important class of nitrogen heterocycles with a pyrrolidine-
2,4-dione core structure as a key structural motif. They show a wide range of biological 
activities including antibiotic (Royles, 1995; Hopman et al., 2002), antiviral (Karwowski et 
al., 1992), antifungal (Wolf et al., 1999), cytotoxic (Lang et al., 2006) and enzyme inhibitory 
activities against bacterial DNA-directed RNA polymerases (Reusser, 1976). Tetramic acid 
derivatives with an attached bicyclic hydrocarbon moiety are designated as equisetin-like. 
Equisetin itself has been found in a Fusarium species (Vesonder et al., 1979) while other 
equisetin derivatives came from Trichoderma (Marfori et al., 2002a), Paecilomyces (Lang et 
al., 2005) or Coniochaeta spp. (Segeth et al., 2003). In this chapter, two tetramic acid 
derivatives (11, 15; Fig. 4-3-1) from the marine-derived fungi Beauveria bassiana and 
Microdiplodia sp., with cytotoxic and enzyme inhibitory (human leucocyte elastase) activity 
are described. 
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 Figure 4-3-1:  Chemical structures of compounds 11 and 15. 
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The fungus Beauveria bassiana is a well-known insect pathogenic mitosporic fungus and the 
most widely used mycopesticide for biological control of insect pests (Devi et al., 2006). It 
has been shown to produce several secondary metabolites, including the antibiotic and 
cytotoxic cyclic peptides beauvericin (Hamill et al., 1969), bassianolide (Nakajyo et al., 
1982) and beauveriolides (Namatame et al., 1999), the antiviral 2-pyridone tenellin (Wat et 
al., 1977) and the dibenzoquinone oosporein (Wainwright et al., 1986). 
 
Fungi of the genus Microdiplodia are little investigated. Some of these species are known to 
be plant pathogens that cause stem rot (Humphreys-Jones, 1981). Only a few secondary 
metabolites were isolated from Microdiplodia spp.. Among these are the xanthone derivatives 
2-hydroxyvertixanthone, vertixanthone and barleriaquinone II, the anthraquinone chryso-
phanol and the steroid ergosterol (Hussain et al., 2007). 
 
During our screening for new and cytotoxic fungal metabolites, we embarked onto a study of 
the marine-derived fungus B. bassiana that was isolated from the sponge Myxilla incrustans, 
collected from the North Sea. The crude extract showed significant cytotoxicity and was thus 
chosen for further examination (Fig. 4-3-2).  
 
 
 
 
Test/control (T/C) value smaller than 30 %, green; 30 – 50 %, yellow, higher than 50 %, red. 
 
Figure 4-3-2:  Screening results of cytotoxicity bioassay of the crude extract of B. bassiana 
(P321BMS). Conc. of all samples: 10 µg mL-1. 
 
Bioassay-guided isolation led to the discovery of a new equisetin-like tetramic acid 
derivative, beauversetin (11). To our knowledge, 11 is the first equisetin analogue isolated 
from a Beauveria sp. The structure elucidation was based on 1H- and 13C-NMR spectroscopy, 
mass spectrometry, UV and CD measurements. Additionally, the two known furan derivatives 
5-hydroxymethyl-furan-2-carboxylic acid (12; Klemke, 2004) and 2-furoic acid (13; Hong et 
al., 1982), and the depsipeptide beauvericin (14; Hamill et al., 1969) were identified. 
 
 
2. run both runs
cell line: Tumor Typ / Name / FU control 1. + 2. Run
mean s.d. GXF LXFL MAXF MEXF RXF UXF mean s.d. GXF LXFL MAXF MEXF RXF UXF mean tot.
compound % T/C [%] [%] 251L 529L 401NL 462NL 486L 1138L % T/C [%] [%] 251L 529L 401NL 462NL 486L 1138L T/C act.**
P321BMS 100 12 6 22 4 11 14 14 7 83 16 10 34 7 15 15 12 9 14 11
1. run
cell line: Tumor Typ / Name / FU control
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From Microdiplodia sp., we have isolated the tetramic acid derivative sch210972 (15; Yang et 
al., 2006a). The compound showed good activity in the HLE inhibition assay with a mean 
IC50 value of 1.04 µg mL-1. Furthermore the phenolic structures 4-oxo-phenyl-butyric acid 
(16; Tomassini et al., 1994) and WF-3681 (17; Namiki et al., 1987) were identified by 
various spectroscopic methods. Compound 15 represents a new structural type for the 
development of HLE inhibitors.  
 
Human leukocyte elastase (HLE) belongs to the chymotrypsin family of serine proteinases. 
HLE is located in the azurophilic granules of polymorphonuclear leukocytes and aids in the 
migration of neutrophils from blood to various tissues such as the airways in response to 
chemotactic factors (Varga et al., 2003). It is suggested that HLE may play a role in several 
diseases, such as pulmonary emphysema (Janoff, 1985), chronic bronchitis (Llewellyn-Jones 
et al., 1996), acute respiratory distress syndrome (Lee et al., 1981), and other inflammatory 
diseases (Adeyemi et al., 1985).   
4.3.1 Cultivation and isolation 
The sponge Myxilla incrustans was collected from the waters around the island of Helgoland. 
The fungus Beauveria bassiana was isolated from the sponge by the former Ph.D. student U. 
Höller as described in chapter 3.2.2.  
The fungus Microdiplodia sp. was isolated from the sea weed Enteromorpha sp. collected 
from the Baltic See waters around the island of Fehmarn. Microdiplodia sp. was isolated from 
the sea weed by the former Ph.D. student C. Klemke (see 3.2.1). Briefly, sea weed sample 
pieces were placed on isolation agar after sterilization. Fungal colonies were transferred to a 
special alga agar, and pure cultures were then transferred to biomalt agar and biomalt salt 
agar. Agar for sporulation was used to identify the fungus.  
Beauveria bassiana was cultivated at room 
temperature for five weeks in 11 L (44 Fernbach 
flasks) of solid biomalt-glucose medium (Fig. 4-3-3). 
Mycelia and medium were homogenized using an 
Ultra-Turrax. The resulting mixture was exhaustively 
extracted with EtOAc (3 × 7 L) and filtered. After 
evaporation of the organic phase 7.25 g of yellowish 
Figure 4-3-3: Culture of B. bassiana  
on solid biomalt-glucose medium. 
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oil was obtained. This was fractionated by VLC, using gradient elution from PE to EtOAc, 
followed by acetone and MeOH, to yield 15 fractions. Due to its promising cytotoxic activity, 
fraction 10 was chosen for further investigation. It was fractionated on RP-VLC, employing 
gradient elution from 10:90 H2O/MeOH to MeOH, to yield six fractions (10A-10F). The 
hydrophilic fraction 10A was separated via HPLC (eluent 40:10:10 PE/EtOAc/acetone) to 
yield three fractions. Fraction 10A2 (30 mg) revealed to be a non-separable mixture of 12 and 
13. Observing cytotoxic activity in fractions 10 D-F, these were further examined. After 
purification via RP-HPLC (eluent 75:25 MeOH/H2O to 100 % MeOH in 20 min), fraction 
10F yielded 2.6 mg of 11. On the basis of TLC results, VLC fractions 5 and 6 were combined 
and then purified via RP-HPLC (eluent 35:65 MeOH/H2O to 75:25 MeOH/H2O in 20 min, 
holding steady for 10 min) to yield 20 mg of 14. Fraction 7 was purified via RP-HPLC (eluent 
65:35 MeOH/H2O to 75:25 MeOH/H2O in 10 min and to 100 % MeOH in further 20 min) and 
yielded further 1.6 mg of 14. 
Microdiplodia sp. was cultivated at room temperature for eight weeks in 10.5 L (42 Fernbach 
flasks) of solid malt-yeast agar medium. Mycelia and medium were homogenized with an 
Ultra-Turrax. The resulting mixture was exhaustively extracted with EtOAc (3 × 7 L) and 
filtered. After evaporation of the organic phase 5.9 g of a brown crude extract was obtained. 
This extract was fractionated by vacuum VLC, using gradient elution from PE to EtOAc, 
followed by acetone and MeOH, to yield 11 fractions. Due to moderate antibiotic activity, 
fraction 2 was chosen for further investigation. It was separated by NP-VLC (gradient elution 
from PE to EtOAc, followed by MeOH) and yielded 10 fractions (C2.1-C2.10). Fraction C2.2 
was further separated via a Sephadex LH-20 column (eluent MeOH) to give 6 fractions. Of 
these, Fraction C2.22 and C2.23 were subjected to HPLC (eluent 40:60 H2O/MeOH) for 
purification and yielded 15 (~100 mg) and 16 (8 mg). Fraction C2.3 also looked promising for 
further investigation from 1H-NMR spectroscopy and was subjected to a Sephadex LH-20 
column, with MeOH as eluent to give further 14 fractions. Purification of fraction 2.32 via 
RP-HPLC (eluent 80:20 MeOH/H2O) led to pure 15 (83.5 mg) while fraction 2.35 gave 17 
(18 mg) after purification via RP-HPLC (eluent 60:40 MeOH/H2O). 
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4.3.2 Results and Discussion 
4.3.2.1 Structure elucidation of tetramic acid derivatives from B. bassiana and 
Microdiplodia sp. 
The structure of beauversetin (11) was determined by extensive ESI-mass spectrometry as 
well as one and two dimensional NMR studies, including 1H- and 13C-NMR DEPT, 1H-1H 
COSY, 1H-13C HMBC, 1H-13C HSQC, ROESY and selective NOE spectra. 
ESI mass spectral analysis indicated a molecular weight of 399, which was confirmed by high 
resolution mass measurement to give the molecular formula C24H33NO4, implying 9 double 
bond equivalents. The 13C-NMR and DEPT spectra however, only showed 21 carbon atoms 
(Table 4-3-1). Four of these could be determined as methyl groups, two of which (CH3-17 and 
CH3-18) had to be bound to a double bond. The resonance signal for CH3-19, showing a 
doublet and possessing a chemical shift of δ 0.91 in the 1H-NMR spectrum, was located on a 
sp3 hybridized carbon and CH3-12 was bounded to a quaternary carbon. Four of the 13C-NMR 
resonances were due to CH2 moieties, ten were assigned as methines and three as quaternary 
carbons as indicated by the DEPT spectrum. At this point, it was anticipated that the three 
missing carbon resonances, according to the molecular formula were non detectable due to 
their quaternary nature and tautomerizations. 
 
 
 
 
 
 
 
 
 
 
 Figure 4-3-4:  Important 1H-1H COSY and 1H-13C HMBC correlations for 11. 
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The clear deduction of homo- and heteronuclear couplings proved to be extremely difficult 
due to many overlapping signals, however, the elucidation of the planar structure was possible 
based on a few distinctive 1H-1H COSY and 1H-13C HMBC correlations. Interpretation of the 
1H-1H COSY spectrum enabled us to elucidate four fragments of the structure of 11 (Fig. 4-3-
4). Thus, the partial structure CH-3 to CH3-17 was established due to 1H-1H couplings from 
H-3 through to H3-17. Connection of CH-5 and CH-6 was also evident from mutual 
correlations in the 1H-1H COSY data, and H-5 additionally coupled to CH3-18. Furthermore, 
the 13C-NMR chemical shift of C-4 (δC 133.5) indicated this quaternary carbon to be sp2-
hybridized and thus to be connected to C-5 via a double bond. C-4 is consequently placed 
between C-5 and CH3-18, resulting in fragment 2. The third fragment, CH2-7 to CH-11, was 
established because of 1H-1H COSY correlations between H2-7 and H-8, CH3-19 to H-8, and 
couplings from H-8 through to H-11. The downfield shifts in the 1H-NMR spectrum for the 
protons at C-6’ and C-5’ (δ 3.58 and 3.90 for H-6’ and δ 3.69 for H-5’) indicated both carbons 
to bear a heteroatom each. Furthermore, 1H-1H COSY and 1H-13C HMBC correlations 
between CH-5’ and CH2-6’ evidenced that CH-5’ must be linked to CH2-6’ to form 
fragment 4.  
 
Proof for the connection of the described fragments came from interpretation of 1H-13C 
HMBC data. The linkage of fragments 1 and 2 was clear from HMBC correlations observed 
from H-3 to C-5 and C-18. HMBC long range correlations between H-7a and C-5 led to the 
linkage of fragments 2 and 3 via CH2-7. C-2 and C-3 are connected due to an observed 
HMBC coupling from H-3 to C-2, and CH3-12 must be linked to C-2, as interpreted from the 
1H-13C HMBC correlations for H3-12 to C-2. Ring closure was done by connection of CH-11 
and C-2 because of an observed ROESY correlation between H-11 and H-13, indicating a 
spatial closeness of these protons, suggesting a decaline system within 11, which was secured 
from further HMBC, and also ROESY correlations, as well as comparison of NMR data with 
those of similar structures (Singh et al., 1998). Thus connection of C-6 and C-11 was 
confirmed by comparison of the chemical shifts for these carbons with those published for 
phomasetin (Singh et al., 1998), showing close to identical data, which makes a bicyclic 
decaline moiety as shown in figure 4-3-4 most likely. 
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Atom 
number 
δC in ppm  δH in ppm, mult.,  
J [Hz]* 
1H-1H COSY-
Correlations 
HMBC-
Correlations  
ROESY-
Correlations 
1 
2 
3 
4 
5 
6 
7 
 
8 
9 
 
10 
 
11 
12 
13 
14 
15 
16 
17 
18 
19 
1’ 
2’ 
3’ 
4’ 
5’ 
6’ 
   n.d. 
  52.4 (C) 
  48.1 (CH) 
133.5 (C) 
127.1 (CH) 
  40.9 (CH) 
  44.3 (CH2) 
 
  34.9 (CH) 
  37.7 (CH2) 
 
  30.8 (CH2) 
 
  41.8 (CH) 
  13.7 (CH3) 
133.7 (CH) 
132.3 (CH) 
133.5 (CH) 
127.6 (CH) 
  18.1 (CH3) 
  22.7 (CH3) 
  23.1 (CH3) 
  - 
  n.d. 
102.9 (C) 
  n.d. 
  63.2 (CH) 
  65.2 (CH2) 
 
 
 
 
 
3.93, d, 10.0 
 
5.15, s 
1.75* 
a: 0.74, d, 12.3 
b: 1.76, d, 12.3 
1.43, m 
b: 0.96* 
a: 1.57* 
a: 0.75* 
b: 1.79* 
1.58* 
1.28, s 
5.26, dd, 10.0, 14.1 
5.82, dd, 10.0, 14.1 
5.89, dd, 10.0, 14.8 
5.48, dd, 6.3, 14.8 
1.69, d, 6.3 
1.58, s 
0.91, d, 6.6 
 
 
 
 
3.69, dd, 5.3, 9.1 
a: 3.90, d, 5.3 
b: 3.58, dd, 5.3, 9.1 
 
 
13, 14 
 
6, 18 
5 
7b, 8 
7a 
7a, 7b, 9b,19 
9a 
 
9a, 10b 
10a, 11 
10b 
 
3, 14 
13, 15 
13, 16, 17 
15, 17 
15, 16 
3, 5, 6 
8 
 
 
 
 
6’a, 6’b 
5’, 6’b 
5’, 6’a 
 
 
2, 5, 12, 14, 18 
 
3, 18 
5, 18 
5, 19 
 
19 
19 
 
 
 
 
2 
3 
16 
13, 14 
14, 17 
 
 
8 
 
 
 
 
6’b 
5’ 
5’ 
 
 
12, 14, 18 
 
 
 
 
 
 
 
11 
 
 
 
3, 6 
11 
3, 16 
 
14 
13, 15 
3, 5, 14 
 
 
 
 
 
 
 
 
*multiplicities and coupling constants partly not identifiable due to overlapping signals. 
n.d. = not detected 
Table 4-3-1: NMR-spectral data of 11 measured in MeOD at 300 and 500 MHz. 
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Remaining to be assigned at this point were the nitrogen atom as well as the quaternary 
carbon resonating at δ 102.9, and three further probably quaternary carbons not detectable in 
the 13C-NMR spectrum. Furthermore, fragment 4 had to be incorporated into the structure of 
11. The weak 13C-NMR signal and the unusual chemical shift of C-3’ (δC 102.9) indicated 
that C-3’ was part of a double bond in conjugation with carbonyl or carbon-hydroxyl 
functionalities allowing tautomerization reactions. These features, including the presence of 
the nitrogen atom suggested a tetramic acid moiety with ring closure via C-5’ (δC 63.2). C-1, 
the third quaternary carbon in neighbourhood to C-3’, together with an attached hydroxyl 
group is then part of the tautomeric system neighbouring C-3’, linking the tetramic acid 
moiety to the decaline system. This suggestion also matched with the number of double bond 
equivalents remaining to be accounted for and the accurate mass determined for 11. The 
possibility of keto-enol tautomerization within this substructure explains the absence of 
signals for C-2’, C-4’ and C-1 and the only weak signal of C-3’ in the 13C-NMR spectrum of 
11. For other “Setins” it had also been reported that 13C-NMR signals for the carbons C-2’, C-
4’ and C-1 were non-detectable (Marfori et al., 2002a; Lang et al., 2005), which in a few 
cases could be solved by measuring the sample at -20° C, thus minimizing tautomerism 
reactions. 
 
Comparison of the NMR data for 11 with those of other equisetin-like derivatives, e. g. 
phomasetin and equisetin, revealed almost identical spectroscopic data and thus confirmed the 
deduced structure for 11 (Singh et al., 1998; Phillips et al., 1989). Significant differences in 
the 1H- and 13C-NMR chemical shifts for phomasetin (Singh et al., 1998) and 11 were only 
present for the tetramic acid fragment. Thus, taking into consideration the lack of the N-
methyl signal in the 1H- and 13C-NMR spectra of 11, the methyl group connected to the 
nitrogen N-1’, as it is the case for phomasetin, was replaced by a hydrogen atom in 11. This is 
also consistent with the mass spectral data, showing a mass reduction of 14 Da compared to 
the molecular weight of phomasetin. 
 
The relative configuration of 11 was mainly determined by interpretation of the observed 
ROESY correlations and CD measurements. Mutual ROESY correlations between H3-12 and 
H-3 as well as correlations from H3-12 to H-6 established CH3-12, H-3 and H-6 to be on the 
same side of the molecule (Fig. 4-3-5). H-11 is placed on the other side of the molecule, i. e. 
β, due to the ROESY correlations between CH-13 and CH-11, resulting in a trans-connection 
of the rings of the decaline moiety. The 6, 11-trans ring fusion of the decaline ring is further 
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supported by the absence of a cross peak between H-6 and H-11 in the ROESY experiment. 
Mutual ROESY correlations between H-14 and H-16, as well as between H-13, H-15 and H3-
17 proved the double bonds in the side chain to be E-configurated. Unfortunately, due to 
overlapping signals in the 1H-NMR spectrum, selective NOE measurements did not give any 
further information regarding the relative configuration at C-8. However, to date, all “Setins” 
reported in the literature possess the same relative configuration at C-8, with CH3-19 being β 
and at the same side of the molecule as the proton at C-11. 
 
 
  
 
 
 
 
 
 Figure 4-3-5:  Important ROESY correlations for 11. 
 
Due to the lack of signals in the ROESY spectrum, the relative stereochemistry of the tetramic 
acid part could not be solved by NMR measurements. Thus a CD spectrum was recorded that 
showed Cotton effects with maxima at 201 nm (∆ε = - 2.4), 236 (+ 6.9), 258 (+ 1.2) and 278 
(+ 4.8). Also, the specific optical rotation (+ 122) was measured, and all chiroptical data were 
compared with the values reported for phomasetin and equisetin (Singh et al., 1998; Phillips 
et al., 1989). The measured data proved to be comparable to those for phomasetin, and were 
opposite to those of equisetin. This led to the conclusion that C-5’ is most probably S-
configurated, as in phomasetin (Table 4-3-2). 
 
[α]D (CHCl3) of 11 [α]D (CHCl3) of 
phomasetin 
[α]D (CHCl3) of 
equisetin 
Cotton effects in the 
CD spectrum of 11 
(CH3CN) 
Cotton effects in the CD 
spectrum of phomasetin 
(CH3OH) 
Cotton effects in the 
CD spectrum of 
equisetin (CH3OH) 
 
[α]25D = +122  
(c = 0.77) 
 
[α]22D= +93.9  
(c = 1.05) 
 
[α]22D = -273 
(c = 0.77) 
 
∆ε = 201 (-2.4) 
∆ε = 236 (+6.9) 
∆ε = 258 (+1.2) 
∆ε = 278 (+4.8) 
 
∆ε = 225 (+3.2) 
∆ε = 232 (+4.4) 
∆ε = 260 (+1.0) 
∆ε = 290 (+5.2) 
 
∆ε = 227 (-5.5) 
∆ε = 235 (-7.5) 
∆ε = 260 (- 3.0) 
∆ε = 290 (-8.9) 
Table 4-3-2:  Chiroptical data of compound 11 in comparison with published values of equisetin and 
phomasetin given in the literature. 
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Extensive evaluation of one and two dimensional NMR and mass spectrometric data for the 
Microdiplodia-derived compound 15 indicated the presence of a tetramic acid structural part 
and a hydrocarbon-type subunit and thus to possess a similar chemical structure as compound 
11. The obtained NMR data as well as the measured optical rotation ([α]22D = + 55.5) were 
thus compared with values published in the literature for other, structurally similar tetramic 
acid derivatives. The spectroscopic data of compound 15 revealed to be identical to those of 
the tetramic acid derivative sch210972 (Yang et al., 2006). The structure of compound 15 is 
thus determined to be identical to that of sch210972.  
 
Beauversetin (11): 
C24H33NO4 (399.24) 
Yellow amorphous powder (2.6 mg), [α]22D = + 122 (CHCl3, c 0.24). 
1H- and 13C-NMR: see table 4-3-1;  
ESI-MS: m/z (% rel int), 400.1 (100) [M + H]+, HRESIMS m/z 422.2301 [M + Na]+ (calcd. 
for C24H33NO4Na+ m/z 422.2302). 
UV: (CH3CN) λmax (log ε): 285 (4.6), 235 (4.2) nm;  
CD: (CH3CN) λmax (∆ε): 330 (0), 278 (+ 4.8), 258 (+ 1.2), 236 (+ 6.9), 201 (- 2.4);  
In vitro antitumor assay: mean IC50 = 3.09 µg mL-1 
Agar diffusion test: not active 
 
 
Sch210972 (15): 
Amorphous white powder (83.5 mg); [α]22D = + 55.5 (MeOH, c 0.1) 
1H-NMR [300 MHz, (CD3)2CO]: δ = 0.84 (3H, d, H3-16, J = 6.5), 0.91 (3H, d, H3-15, J = 
6.5), 0.98 (1H, d, H-6a, J = 13.1), 1.39 (1H, dd, H-9, J = 4.4; 8.8), 1.49 (2H, s, H3-14 / H3-24), 
1.56 (3H, s, H3-12), 1.64 (1H, d, H-8a, J = 10.8), 1.75 (1H, dd, H-22a, J = 4.4; 10.3), 1.83 (1H, 
d, H-5, J = 10.8), 1.91 (1H, d, H-6b, J = 13.1), 2.50 (1H, dd, H-22b, J = 2.9; 13.1), 3.00 (1H, t, 
H-2, J = 7.7), 3.80 (1H, dd, H-20, J = 2.9; 10.3), 3.94 (1H, dd, H-1, 7.7; 8.8), 5.19 (1H, m, H-
13), 5.66 (2H, s, H-3 / H-4); 
13C-NMR [75.5 MHz, (CD3)2CO]: δ = 14.3 (q, C-14), 16.6 (q, C-12), 21.9 (q, C-16), 23.2 (q, 
C-15), 28.2 (q, C-24), 33.8 (d, C-7), 40.4 (d, C-9), 41.7 (d, C-5), 43.1 (t, C-6), 43.2 (t, C-22), 
47.1 (t, C-8), 47.4 (d, C-1), 48.9 (d, C-2), 50.3 (s, C-10), 61.4 (d, C-20), 75.7 (s, C-23), 101.9 
(s, C-18), 122.7 (d, C-13), 129.9 (d, C-3), 134.9 (d, C-4), 136.7 (s, C-11), 177.1 (s, C-19), 
177.8 (s, C-25), 194.0 (s, C-21), 195.4 (s, C-17); 
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ESI-MS: m/z 446 [M + H]+; 
HLE inhibition assay: active (mean IC50 = 1.04 µg mL-1) 
In vitro antitumor assay: not active 
Agar diffusion test: moderate activity against B. megaterium (GI 1.5 mm) 
Literature: Yang et al., 2006. 
 
4.3.2.2 Other secondary metabolites from Beauveria bassiana and Microdiplodia sp. 
a) Beauveria bassiana 
 
From B. bassiana, the two furane derivatives, 5-hydroxymethyl-furan-2-carboxylic acid (12) 
and 2-furoic acid (13) were elucidated by one and two dimensional NMR spectroscopy and 
comparison with previous results from our group (Klemke, 2004). They are very common 
compounds that are used in synthesis work, but have also been isolated from many 
microorganisms, such as Aspergillus spp., Gibberella fujikuroi or Pseudomonas spp. (Sumiki 
et al., 1929; Kawarada et al., 1955; and other). 2-Furoic acid has often been used in feeding 
experiments, serving as carbon source and precursor for secondary metabolites (Jones et al., 
1968; Trugdill, 1969; Kitcher et al., 1970). Compound 14 (beauvericin) was first isolated by 
Hamill and co-workers and has been found to be a major secondary metabolite of Beauveria 
bassiana as well as several Paecilomyces and Fusarium spp. (Klaric et al., 2005). The 
structure was determined by spectroscopic measurements and comparison with published data 
(Hamill et al., 1969). 
 
 
 
 
 
 
 
 
 
 
Figure 4-3-6:  Structures of compounds 12-14, isolated from Beauveria bassiana. 
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5-Hydroxymethyl-furan-2-carboxylic acid (12): 
Colourless powder 
1H-NMR [300 MHz, CD3OD]: δ = 4.56 (2-H, s, H-6), 6.41 (1-H, d, H-5, J = 3.29), 7.03 (1-
H, d, H-4, 3.29); 
13C-NMR [300 MHz, CD3OD]: δ = 57.6 (t, C-6), 110.0 (d, C-5), 117.36 (d, C-4), 158.72 (s, 
C-2); 
ESI-MS: m/z 142.5  
Literature: Klemke, 2004.  
 
 
2-Furoic acid (13): 
White crystalline powder 
1H-NMR [300 MHz, CD3OD]: δ = 6.55 (1-H, dd, H-5, J = 1.46, 3.29), 7.08 (1-H, d, H-4, 
3.29), 7.65 (1-H, d, H-2, 1.46); 
13C-NMR [300 MHz, CD3OD]: δ = 112.5 (d, C-5), 116.4 (d, C-4), 145.9 (s, C-3), 146.2 (d, 
C-2), 157.4 (s, C-1); 
ESI-MS: m/z 112.5  
Literature: Hong et al., 1981. 
 
 
Beauvericin (14): 
Yellow amorphous powder (21.4 mg); [α]22D = + 33.2 (CHCl3, c 0.27; Lit: + 65.8, MeOH, 
c 0.1). 
1H-NMR [500 MHz, CD3OD]: δ = 0.27 (9-H, d, H3-15, J = 6.59), 0.90 (9-H, d, H3-14, 6.59), 
1.83 (3-H, m, H-13), 3.06 (3-H, dd, H-11b , 12.08, 14.27), 3.17 (9-H, s, H3-12), 3.43 (3-H, dd, 
H-11a, 4.39, 14.27), 4.87 (3-H, d, H-9, 8.78), 5.83 (3-H, dd, H-10, 4.39, 12.08), 7.23 (3-H, m, 
H-8), 7.29 (6-H, s, H-6/H-7), 7.31 (6-H, s, H-4/H-5); 
13C-NMR [500 MHz, CD3OD]: δ = 17.1 (q, C-15), 19.1 (q, C-14), 31.2 (d, C-13), 32.2 (q, C-
12), 35.4 (t, C-11), 57.8 (d, C-10), 77.2 (d, C-9), 128.0 (s, C-8), 129.7 (6-C, d, C-6/C-7), 
129.8 (6-C, d, C-4/C-5), 138.1 (s, C-3), 170.9 (s, C-2), 173.1 (s, C-1); 
ESI-MS: m/z 783.5  
In vitro antitumor assay: mean IC50 = 3.09 µg mL-1 
Agar diffusion test: not active 
Literature: Hamill et al., 1969. 
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b) Microdiplodia sp. 
 
Compounds 16 and 17 have been isolated from Microdiplodia sp. in addition to compound 
15. From 1H- and 13C-NMR and LCMS spectral data and comparison of the obtained data 
with the values published in the literature, it was evident that 16 is identical with 4-oxo-
phenyl-butyric acid. The structure is well known from synthesis studies (Tomassini et al., 
1994) and is most probably an intermediate product in fungal secondary metabolism. 
Compound 17 proved to be the propionic acid derivative WF-3681 (Nishikawa et al., 1987; 
Namiki et al., 1987) after interpretation of the 1H- and 13C-NMR spectral data and comparison 
with the published NMR values. It has first been isolated from the sphaeropsidaceous fungus 
Chatomella raphigera Swift No. 3681. 17 is optically inactive, which supports the assumption 
to be present as a racemic mixture made by Nishikawa and co-workers. 
 
OH
O
O
O
O
HO
COOH
17
16
 
 
Figure 4-3-7:  Secondary metabolites isolated from Microdiplodia sp.  
 
 
4-Oxo-phenyl-butyric acid (16): 
Yellow oil (8 mg); 
1H-NMR [300 MHz, (CD3)2CO]: δ = 2.76 (2-H, dd, H2-2, J = 5.9 / 6.6), 3.18 (2-H, dd, H2-3, 
5.9 / 6.6), 7.56 (2-H, dd, H-7 / H-9, 7.3 / 8.4), 7.71 (1-H, d, H-8, 7.3), 8.00 (2-H, d, H-6 / H-
10, 8.4); 
13C-NMR [75.5 MHz, (CD3)2CO]: δ = 28.2 (t, C-2), 34.2 (t, C-3), 130.2 (d, C-7 / C-9), 131.5 
(d, C-6 / C-10), 133.6 (s, C-5), 135.9 (d, C-8), 174.4 (s, C-1), 193.5 (s, C-4); 
ESI-MS: m/z 179 [M + H]+; 
HLE inhibition assay: active (mean IC50 = 1.78 µg mL-1) 
Agar diffusion test: moderate activity against B. megaterium (GI 3 mm) 
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In vitro antitumor assay: not active 
Literature: Tomassini et al., 1994 
 
 
WF-3681 (17): 
Amorphous yellowish powder (18 mg); 
1H-NMR [300 MHz, (CD3)2CO]: δ = 1.72 (2-H, m, H2-5), 2.50 (2-H, m, H2-6), 5.60 (1-H, 
dd, H-4, J = 1.8 / 8.8), 7.40 (1-H, m, H-11), 7.50 (2-H, m, H-10 / H-12), 7.85 (2-H, m, H-9 / 
H-13); 
13C-NMR [75.5 MHz, (CD3)2CO]: δ = 29.6 (t, C-5), 30.6 (t, C-6), 79.0 (d, C-4), 128.9 (d, C-
C-9 / C-13), 130.0 (d, C-11), 130.1 (d, C-10 / C-12), 130.4 (s, C-8), 132.0 (s, C-3), 139.3 (s, 
C-2), 170.0 (s, C-1), 174.6 (s, C-7); 
ESI-MS: m/z 249 [M + H]+; 
Agar diffusion test: not active 
In vitro antitumor assay: not active 
Literature: Namiki et al., 1987. 
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4.3.3 Biological activities  
A sample of compound 11 (80 % pure) revealed moderate activity in a cytotoxicity test using 
a six cell line panel for a monolayer assay (mean IC50 3.09 µg mL-1; Fig. 4-3-8). Cytotoxic 
activity for 11 is in good accordance with published data for similar structures like 
paecilosetin, which shows an IC50 of 3.1 µg mL-1 (Lang et al., 2005).  
 
 
 Cell line origin: GXF gastric cancer; LXF lung cancer; MAXF, mammary carcinoma; MEXF, melanoma; RXF   
 renal cell cancer; UXF uterine cancer. 
 
 Figure 4-3-8:  Cytotoxic activity of beauversetin in human tumor cell lines in monolayer culture. 
 
Compound 15 was first isolated by Yang and co-workers from the fermentation broth of 
Chaetomium globosum (Yang et al., 2006). It is reported to inhibit the chemokine receptor 
CCR-5. This receptor, belonging to the super-family of seven-transmembrane G-protein 
coupled receptors (GPCRs), has been identified to play an important role in viral attachment 
to and entry into the human host cell in the initial stage of HIV-I infection (Samson et al., 
1996; Berger et al., 1999). Compound 15 showed good activity in the HLE inhibition assay 
with a mean IC50 value of 1.04 µg mL-1. To our knowledge, this activity is reported for the 
first time for a tetramic acid. Furthermore, 15 showed moderate antibiotic activity against 
B. megaterium (growth inhibition zone of 1.5 mm at a concentration of 50 µg/disk), an 
activity often reported for tetramic acid derivatives. The mechanism for the antibiotic activity 
of tetramic acids has been explained by the ability to strongly chelate biochemically 
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indispensable metal ions and to mimic phosphate groups in the binding site of kinases (Peikert 
et al., 2008).  
Compound 16 showed moderate antibiotic properties against B. megaterium. Additionally, the 
compound was active in the HLE inhibition assay, with an IC50 value of 1.78 µg mL-1. 
For compound 17, an inhibition of aldose reductase is described (Nishikawa et al., 1990). 
Aldose reductase is an enzyme that catalyzes the conversion of glucose to sorbitol and thus 
plays an important role in the pathogenesis of diabetic complications. In our test systems, 17 
did not show significant bioactivities.  
 
4.3.4 Biosynthetic considerations for the isolated tetramic acids 
The tetramic acid derivatives isolated during this study are characterized by a decaline ring 
system connected to a pyrrol-2,4-dione moiety and thus can be described as equisetin-like 
tetramic acids. Structural variations for this group of secondary metabolites mostly occur in 
the methylation pattern and in the length of the side chain that is connected to the decaline 
system. We propose that 11 as well as 15 originate from two separate biogenetic units, a 
polyketide part and an amino acid. Additionally, methylation reactions would form the final 
structure. Marfori and co-workers proposed a biogenetic pathway for trichosetin via an 
octaketide intermediate directly derived from eight acetate units attached by a head-to-tail 
fashion, which is typical for the polyketide pathway. The assumption was confirmed by 
incorporation studies with labelled acetate (Marfori et al., 2002b). Consequently, 11 would be 
formed by a nonaketide, increasing the side chain by two carbon atoms to be a five-membered 
chain, while for 15 an octaketide as for trichosetin would be the starting point. For the 
formation of the tetramic acid moiety, the incorporation of an amino acid is proposed, which 
is also proven for the equisetin biosynthesis (Schobert, 2007). Serine would then be the 
precursor for the tetramic acid moiety of 11 and 4-hydroxy-4-methylglutamic acid for 15. The 
methyl groups are likely to originate from the important biological methylation agent S-
adenosylmethionine (SAM).  
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Figure 4-3-9:  Proposed biosynthetic pathway for compound 11. Blue: methylation via SAM.  
 
Recently, an iterative polyketide-synthase-peptide synthetase (PKS/NRPS) hybrid gene has 
been identified in the genome of Fusarium heterosporum, the main producer of equisetin. The 
gene contains all necessary domains for the formation of a polyketide chain and the covalent 
linkage to an amino acid via an amide (Sims et al., 2004). In accordance to the proposed 
biosynthesis for equisetin, the intermediates of compounds 11 and 15 undergo spontaneous 
cyclization and oxidation reactions to yield the tetramic acid, respectively (Fig. 4-3-9). 
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4.4 Alternaria japonica (strain 194) 
Fungi belonging to the genus Alternaria are well-known due to their ubiquitous occurrence. 
They are a natural part of the fungal flora almost everywhere and known as plant pathogens. 
Some species however are also used as biocontrol agents against invasive plant species 
(Shabana et al., 1996). Terrestrial as well as facultative marine species have been 
investigated, and the major pathogenic compounds produced by Alternaria spp., such as 
alternariol or altertoxin, are well characterized (Fehr et al., 2008; Andersen et al., 2008).  
 
Alternaria japonica has been chosen for cultivation and bioassay-guided investigation due to 
its good results during the screening for cytotoxic activity and interesting 1H-NMR spectra 
and LC-MS data. The dominating compound produced by the investigated fungus was 
pachybasin (18, Shibata et al., 1955). In minor quantities, the presence of chrysophanol (19, 
Howard & Raistrick, 1950) was observed. Both compounds are well-known anthraquinone 
derivatives. 
 
 
 
Test/control (T/C) value smaller than 30 %, green; 30 – 50 %, yellow, higher than 50 %, red. 
 
Figure 4-4-1:  Screening results of cytotoxicity bioassay of the crude extract of A. japonica 
(P194MYA). Conc. of all samples: 10 µg mL-1. 
 
4.4.1 Cultivation and secondary metabolite isolation 
The fungus Alternaria japonica was isolated by the former Ph.D. student U. Höller from an 
unidentified alga collected from the waters around the Island of Tenerife. The isolation 
procedure was carried out as described in chapter 3.2.1. 
 
The fungus was cultivated at room temperature for two months in 6.75 L (27 Fernbach flasks) 
of solid malt-yeast agar medium. The fungal biomass, including the medium, was 
homogenized and the resulting mixture was exhaustively extracted with EtOAc (3 × 5 L) and 
filtered. The filtrate was evaporated to yield 779.6 mg of a brown crude extract. This extract  
1. run 2. run both runs
1. + 2. Run
mean s.d. GXF LXFL MAXF MEXF RXF UXF mean s.d. GXF LXFL MAXF MEXF RXF UXF mean tot. %
compound % T/C [%] [%] 251L 529L 401NL 462NL 486L 1138L % T/C [%] [%] 251L 529L 401NL 462NL 486L 1138L T/C act.** act.*
P194MYA 83 18 9 32 13 16 18 20 6 0 49 11 44 44 52 50 69 37 33 5 42
cell line: Tumor Typ / Name / FU control cell line: Tumor Typ / Name / FU control
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was fractionated by VLC, using gradient elution from PE to EtOAc, followed by acetone and 
MeOH, to yield 18 fractions. Fraction 2 revealed to be pure 18 (63.8 mg). Fraction 4 was 
subjected to RP-18 HPLC (eluent 50:10 MeOH/H2O) and 42.3 mg of semi-pure 19. Fractions 
6 and 7 were combined and subjected to RP-HPLC (eluent 90:10 MeOH/H2O to 100 % 
MeOH in 15 min) to give four fractions. Structure elucidation of these fractions could not be 
performed due to the small amount and instability of the isolated substances.  
 
4.4.2 Results and discussion 
Structure elucidation of 18 and 19 was accomplished by 1H- and 13C-NMR spectroscopy, LC-
MS analysis and comparison with literature values. From interpretation of the spectroscopic 
data, it was clear that both structures must belong to the groups of anthraquinones. 
Comparison of the measured values with those obtained from a literature search for 
anthraquinone derivatives confirmed compound 18 to be identical to pachybasin (Shibata et 
al., 1955) and conmpound 19 to be chrysophanol (Howard & Raistrick, 1950). 
 
OH
CH3
O
O
OH
CH3
O
O
18 (pachybasin)
19 (chrysophanol)
OH
 
 
 Figure 4-4-2:  Chemical structures of 18 and 19. 
 
Pachybasin (18) was formerly isolated as the colouring agent of the fungus Pachybasium 
candidum by Shibata and co-workers (Shibata et al., 1955) while chrysophanol (19) has been 
found in many plants as well as fungi (Howard & Raistrick, 1950). Chrysophanol is a highly 
active mycotoxin against powdery mildew, one of the most serious plant diseases causing 
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large yield losses in a number of crops (Choi et al., 2004). Chrysophanol is known to act 
synergistically together with other anthraquinones such as physcion (Yang et al., 2006b). 
 
The high cytotoxicity found in the screening could not be recovered from the extract of the 
fungus. Only VLC fraction 13 showed weak cytotoxic activity with an average IC50 value of 
30.6 µg mL-1, but was not further purified because of its small quantity (4 mg). Based on its 
interesting 1H-NMR data, fraction 11 was further investigated. After separation, the obtained 
fractions exhibited weak cytotoxicity suggesting an accumulation of potentially cytotoxic 
metabolites. Unfortunately, the purified compounds were not stable enough to determine their 
structure.  
 
Pachybasin (18): 
C15H10O3 (238.28) 
Yellow amorphous solid (63.8 mg); 
1H-NMR [300 MHz, CD3Cl]: δ = 2.44 (3H, s, H3-15), 7.07 (1H, s, H-6), 7.60 (1H, s, H-4), 
7.78 (2H, m, H-11 / H-12), 8.26 (2H, m, H-10 / H-13), 12.54 (1H, s, OH-16); 
13C-NMR [75.5 MHz, CD3Cl]: δ = 22.3 (q, C-15), 114.0 (s, C-2), 120.8 (d, C-4), 124.08 (d, 
C-6), 126.7 (d, C-13), 127.3 (d, C-10), 133.0 (s, C-9), 133.2 (s, C-14), 133.5 (s, C-7), 134.1 
(d, C-11), 134.4 (d, C-12), 148.6 (s, C-5), 162.7 (s, C-3), 182.6 (s, C-8), 188.0 (s, C-1); 
ESI-MS: m/z 255.4 [M – H + H2O]-; 
Literature: Shibata et al., 1955;  
 
Chrysophanol (19): 
C15H10O4 (254.24) 
Yellow solid (42.3 mg), semi-pure; 
1H-NMR [300 MHz, (CD3)2CO]: δ = 2.49 (s, H3-19), 7.13 (s, H-12), 7.21 (d, H-4, J = 6.6), 
7.24 (t, H-5, J = 6.6), 7.61-7.63 (br m, H-14), 8.15 (d, H-6, J = 6.6); 
ESI-MS: m/z 252.9 [M – H]-; 
Literature: Howard and Raistrick, 1950. 
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4.5 Trichoderma harzianum (strain 714) 
 
Fungi belonging to the genus Trichoderma are very common findings in the terrestrial as well 
as in the marine habitat. T. harzianum is one of the fungal species most studied for biocontrol 
purposes (Hanson, 2005). The biocontrol potential is assumed to rely on the production of 
peptaibol molecules which, combined with the production of hydrolytic enzymes, strongly 
inhibit growth of fungal plant pathogens (Peltola et al., 2004).  
 
In continuation of our projects aimed at finding new natural products with biological activity 
and novel chemical structures from marine-derived fungi, a Trichoderma harzianum strain 
isolated from the green alga Chaetomorpha linum collected around the Island of Helgoland, 
Germany, was investigated. The crude extract showed promising cytotoxic activity, inhibiting 
tumor cell growth, especially the UXF (uterus carcinoma) and the MAXF (melanoma 
xenografts) cell lines. 
 
 
 
 
Test/control (T/C) value smaller than 30 %, green; 30 – 50 %, yellow, higher than 50 %, red. 
 
Figure 4-5-1:  Screening results of cytotoxicity bioassay of the crude extract of T. harzianum 
(P714MYA). Conc. for all samples: 10 µg mL-1. 
 
LC-MS spectra of the crude extract displayed series of ions at m/z [M]+ 960 to 1250, 
indicating the presence of a peptidic mixture. Characteristic signals in the 1H-NMR spectrum, 
showing signals in the region typical for amino acid α-protons at δ 4-5 ppm underlined this 
assumption. Bioassay-guided isolation led to a mixture of peptaibols that are structurally 
similar or identical to the trichorovins (Iida et al., 1995). 
2. run both runs
cell line: Tumor Typ / Name / FU control 1. + 2. Run
mean s.d. GXF LXFL MAXF MEXF RXF UXF mean s.d. GXF LXFL MAXF MEXF RXF UXF mean tot. %
compound % T/C [%] [%] 251L 529L 401NL 462NL 486L 1138L % T/C [%] [%] 251L 529L 401NL 462NL 486L 1138L T/C act.** act.*
P714MYA 33 47 33 49 39 19 57 104 12 50 41 29 36 22 26 41 99 24 44 5 42
1. run
cell line: Tumor Typ / Name / FU control
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4.5.1 Cultivation and bioassay-guided isolation of secondary metabolites 
The fungus Trichoderma harzianum was isolated from the alga Chaetomorpha linum by E. 
Eguereva. The isolation procedure was done as described in chapter 3.2.1: the alga was 
sterilized and then cut into pieces and placed on agar plates containing isolation medium. 
Fungal colonies growing out of the algal tissue were then transferred to medium for 
sporulation in order to enable taxonomy of the isolates. The fungal strain was identified as 
Trichoderma harzianum by the Centraalbureau voor Schimmelcultures, Utrecht, The 
Netherlands. 
 
The fungus was cultivated at room 
temperature for eight weeks in 10.5 L (42 
Fernbach flasks; Fig. 4-5-2) of solid malt-
yeast agar medium. Mycelia and medium 
were homogenized using an Ultra-Turrax. 
The resulting mixture was exhaustively 
extracted with EtOAc (3 × 7 L) and filtered. 
The filtrate was evaporated to yield 1.08 g of 
a brown crude extract. This extract was 
fractionated by VLC with a PE – EtOAc – 
MeOH gradient, to yield ten fractions, with 
fractions 8, 9 and 10 showing moderate 
cytotoxic activity. Fraction 8 was then separated on a Sephadex LH-20 column, with MeOH 
as eluent to give 14 fractions. Of these, fraction 8.3 was subjected to RP-18 HPLC employing 
gradient elution from 25:75 H2O/MeOH to 5:95 H2O/MeOH in 10 min, followed by 100 % 
MeOH for further 10 min, to yield six fractions. Fraction 5 (tR = 14 min) gave a mixture of 
peptaibols (21, Iida et al., 1995). Fraction 4 (tR = 13.5 min) was further attempted to purify by 
RP-HPLC (eluent 29:71 H2O/MeOH) and gave five fractions. Of these, fraction 4 showed to 
be a mixture of peptaibols as well (20).  
Figure 4-5-2: Culture of T. harzianum in 
Fernbach flasks. 
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Figure 4-5-3:  Isolation scheme for bioassay-guided isolation of 20 and 21. Fractions showing 
cytotoxic activity are marked in orange. 
 
Fraction 1 
72.1 mg 
Fraction 2 
68.7 mg 
Fraction 3 
84.0 mg 
Fraction 4 
68.3 mg 
Fraction 6 
64.3 mg 
Fraction 7 
33.4 mg 
Fraction 8 
332.8 mg 
Fraction 9 
178.1 mg 
Fraction 10 
10.8 mg 
Fraction 5 
72.1 mg 
Fraction 8.1 
50.9 mg 
Fraction 8.2 
93.4 mg 
Fraction 8.3 
49.3 mg 
Fraction 8.4 
>2 mg 
Fraction 8.6 
30.6 mg 
Fraction 8.7 
45.4 mg 
Fraction 8.8 
13.9 mg 
Fraction 8.9 
8.6 mg 
Fraction 8.10 
>2 mg 
Fraction 8.5 
>2 mg 
Fraction 8.11 
>2 mg 
Fraction 8.12 
>2 mg 
Fraction 8.13 
>2 mg 
Fraction 8.14 
>2 mg 
Fraction 83.A 
4 mg 
Fraction 83.B 
17.6 mg 
Fraction 83.C 
1.7 mg 
Fraction 83.D 
33.2 mg 
Fraction 83.F 
38.8 mg 
Peptaibol mixture 
18.2 mg 
Peptaibol mixture 
2.7 mg 
RP-HPLC 
MeOH 
RP-HPLC 
H2O/MeOH 
Crude extract 
1.09 g 
Liquid column 
chromatograpy 
Sephadex, eluent: MeOH 
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4.5.2 Results and discussion 
The 1H-NMR spectrum of the peptidic mixtures 20 and 21 showed several interesting 
resonances in the region of 2.5 ppm to 3 ppm and between 4 and 5 ppm, indicating the 
presence of α - and β-protons of a peptidic structure. This assumption was underlined by the 
13C-NMR spectrum, showing characteristic carbonyl signals in the δC 170-180 ppm region, 
and α-carbon signals between 50 and 70 ppm. Furthermore, a signal corresponding to an 
acetyl group was observed in the 1H-NMR spectrum at δH 2.0 ppm. From LC-MS 
measurements, molecular mass values in the range of 960 to 1280 m/z were observed. These 
data suggested 20 and 21 to be mixtures of 11-residue peptides similar to the trichorovins and 
the trichorozins (Iida et al., 1995; Wada et al., 1995). 
 Trichorovins and trichorozins have been isolated from two Trichoderma species as series of 
peptaibols. Typical for this group of substances is the absence of free carboxyl groups and the 
acetylation of the N-terminal amino acids, as well as the incorporation of α-aminoisobutyric 
acid (Aib) residues into the molecule. Both, trichorovins and trichorozins are groups of 11-
residue linear peptaibols, including 3 Aib residues at the positions 1, 5 and 9. The primary 
structures of the trichorovins are shown in figure 4-5-4.  
 
          1      2      3   4      5       6       7         8       9      10     11 
Ac–Aib–W–X–Y–Aib–Pro–Lxx–Lxx–Aib–Pro–Z 
 
 
 
 
 
 Lxx: Leu or Ile 
 Lxxol: leucinol or isoleucinol 
 Lol: leucinol; Iol: isoleucinol; Vol: valinol 
 
 
 
Figure 4-5-4:  Structures of trichorovins I – XIV. 
 
 
TV   W X Y Z   m/z 
I   Asn Val Lxx Vol   1147 
II   Asn Val Val Lxxol   1147 
III   Gln Val Val Lxxol   1161 
IV   Gln Val Val Lxxol   1161 
V   Asn Val Lxx Lxxol   1161 
VI   Asn Val Lxx Lxxol   1161 
VII   Asn Lxx Val Lxxol   1161 
VIII   Gln Val Lxx Lxxol   1175 
IX   Gln Val Lxx Lxxol   1175 
X   Gln Lxx Val Lxxol   1175 
XI   Asn Lxx Lxx Lxxol   1175 
XII   Asn Ile Ile Iol   1175 
XIII   Gln Lxx Lxx Lxxol   1189 
XIV   Gln Lxx Lxx Lxxol   1189 
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The trichorovins are described in literature as a mixture of peptaibols with molecular masses 
between 1147 and 1187. The mass differences of 14 Da in the structural analogues stem from 
the replacement of leucine or isoleucine by valine or from the exchange of asparagine by 
glutamine. They display characteristic fragmentation patterns that result from cleavage at the 
unstable Aib-Pro bonds in the molecule. As shown in figure 4-5-5 for trichorovin XII, 
cleavage between Aib-9 and Pro-10 leads to a fragment of m/z 961. This is further 
fractionated into two fragments of 553 and 409 Da, respectively.  
 
 
 
Figure 4-5-5:  Fragmentation pattern of trichorovin XII during FAB-MS measurement (Wada et al., 
1995). 
 
The ESI-MS spectrum of fraction 20 showed a series of ions at m/z 1175, 961, 553 and 409, 
which can be deduced from cleavage reactions between Aib and Pro as described above 
(Fig. 4-5-5), suggesting the presence of structures similar to those of trichorovins VIII to XII. 
The molecular ion of m/z 1161 could also be observed in minor quantities, indicating the 
presence of further trichorovins or related structures. The fragmentation pattern of 21 m/z 
1189, 975, 567 and 409 shows analogy to that of trichorovins XIII and XIV. The difference of 
1 Da in the molecular weight visible in the spectra is explainable by the presence of the 
carboxyl form of glutamine or asparagine in the structure (Fig. 4-5-6). The exact structures of 
the compounds in 20 and 21 should be confirmed by further investigations. 
Ac–Aib1–Asn2–Lxx3–Lxx4–Aib5–Pro6–Lxx7–Lxx8–Aib9–Pro10–Lxxol11 
[Ac–Aib1–Asn2–Lxx3–Lxx4–Aib5–Pro6–Lxx7–Lxx8–Aib9]+
[H–Pro10–Lxxol11]+
[Ac–Aib1–Asn2–Lxx3–Lxx4–Aib5]+ [H–Pro6–Lxx7–Lxx8–Aib9]+ 
m/z 215 
m/z 961 
m/z 409 m/z 553 
H+
H+
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A 
 +Q1: Exp 2, 23,573 to 23,759 min from Sample 5 (KNF83E) of 2007-09-13.wiff (Turbo Spray), subtracted (23,954 to 27,434 min and 18,45 to 23,45... Max. 6,6e6 cps.
200 300 400 500 600 700 800 900 1000 1100 1200 1300 1400 1500
m/z, amu
5,0e5
1,0e6
1,5e6
2,0e6
2,5e6
3,0e6
3,5e6
4,0e6
4,5e6
5,0e6
5,5e6
6,0e6
6,5e6
In
te
ns
ity
, c
ps
975,8
976,8
567,8
1190,3
623,7409,8
482,5
990,2
369,5215,4
324,5 582,0256,1
961,8
496,5 904,8 1203,8
1176,1381,5 891,0553,8 609,5216,6 992,7270,3 1119,3296,6 1221,4919,0777,8711,7440,9 637,5 819,8 1434,81421,81003,3 1293,7
 
B 
 +Q1: Exp 2, 22,684 to 22,938 min from Sample 2 (KN 714 F 83 D 4) of 2008-02-29.wiff (Turbo Spray), subtracted (15,087 to 22,621 min and 23,06 ... Max. 5,0e6 cps.
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Figure 4-5-6:  ESIMS spectra of peptaibol mixtures 20 (A) and 21 (B) in positive mode. 
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4.5.3 Biological activities 
Based on the screening results, the VLC fractions obtained after separation of the crude 
extract were investigated for cytotoxic activity. Fractions 8, 9 and 10 showed moderate 
activities with mean IC70 values in the range of 14.8 to 21.4 µg mL-1. Bioassay-guided 
isolation led to the above-described mixtures of peptaibols. Fractions 83.D1 through 83.D4 
were not tested due to the small amount obtained. Fraction 83.D, however exhibited an IC70 
value of 17.6 µg mL-1 (Fig. 4-5-7). The mixture of peptaibols 21, being identical with fraction 
83.E, showed a mean IC70 value of 6.7 µg mL-1. Mixture 21 additionally showed moderate 
antifungal activity against Microbotryum violaceum (GI 2.5 mm, conc. 50 µg/disk). 
 
A 
 
B 
 
 Cell line origin: GXF gastric cancer; LXF lung cancer; MAXF, mammary carcinoma; MEXF, melanoma; RXF   
 renal cell cancer; UXF uterine cancer. 
Figure 4-5-7:  Cytotoxicity of the fractions containing mixture 20 (A), and 21 (B) in human tumor cell 
lines in monolayer culture. 
IN-VITRO ANTITUMOR ACTIVITY OF MNEB552 IN HUMAN TUMOR CELL LINES (Monolayer Assay, PI) 
──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 
TUMOR/  EXP.     CTRL                Distribution of IC70 related to Mean                 IC50        IC70        IC90 
PASSAGE NO.      FLUOR.                         log.scaled axis 
NO.              UNITS *0.01          *0.1                           *10           *100   ug/ml       ug/ml       ug/ml 
─────────────────────────┼──────────────┼────────────Mean─────────────┼──────────────┼────────────────────────────────── 
                                                     6.750 
GXF                      .              .              |              .              . 
251L    IF374OT  2906    .              .              ▀▀▀            .              .   2.774       8.682      28.280 
                         .              .              |              .              . 
LXF                      .              .              |              .              . 
629L    IG374OT  3204    .              .           ▀▀▀▀              .              .   1.745       3.965      16.010 
                         .              .              |              .              . 
MAXF                     .              .              |              .              . 
401NL   IF375OT  2769    .              .         ▀▀▀▀▀▀              .              .   1.567       2.828      18.185 
                         .              .              |              .              . 
MEXF                     .              .              |              .              . 
462NL   IG375OT  2608    .              .              ▀▀▀            .              .   2.721       7.159      19.922 
                         .              .              |              .              . 
RXF                      .              .              |              .              . 
486L    IF376OT  2394    .              .              ▀▀▀▀▀▀▀▀▀▀     .              .  13.155      23.227      41.013 
                         .              .              |              .              . 
UXF                      .              .              |              .              . 
1138L   IG376OT  2115    .              .              ▀              .              .   2.147       5.842      19.629 
                         .              .              |              .              . 
──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 
Mean                     n=6                         6.750                               2.890       6.750      22.566   
 
IN-VITRO ANTITUMOR ACTIVITY OF MNEB551 IN HUMAN TUMOR CELL LINES (Monolayer Assay, PI) 
──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 
TUMOR/  EXP.     CTRL                Distribution of IC70 related to Mean                 IC50        IC70        IC90 
PASSAGE NO.      FLUOR.                         log.scaled axis 
NO.              UNITS *0.01          *0.1                           *10           *100   ug/ml       ug/ml       ug/ml 
─────────────────────────┼──────────────┼────────────Mean─────────────┼──────────────┼────────────────────────────────── 
                                                    17.576 
GXF                      .              .              |              .              . 
251L    IF374OT  2906    .              .              ▀              .              .   9.342      17.263      31.899 
                         .              .              |              .              . 
LXF                      .              .              |              .              . 
629L    IG374OT  3204    .              .            ▀▀▀              .              .   7.086      13.095      24.198 
                         .              .              |              .              . 
MAXF                     .              .              |              .              . 
401NL   IF375OT  2769    .              .              ▀              .              .   9.224      16.174      28.361 
                         .              .              |              .              . 
MEXF                     .              .              |              .              . 
462NL   IG375OT  2608    .              .              ▀              .              .  11.595      17.691      26.992 
                         .              .              |              .              . 
RXF                      .              .              |              .              . 
486L    IF376OT  2394    .              .              ▀▀▀▀▀▀>        .              . >30.000     >30.000     >30.000 
                         .              .              |              .              . 
UXF                      .              .              |              .              . 
1138L   IG376OT  2115    .              .              ▀              .              .   9.003      15.193      25.641 
                         .              .              |              .              . 
──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 
Mean                     n=6                        17.576                              11.141      17.576      27.729   
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Like other peptaibols, trichorovins were reported to exhibit antibiotic properties, caused by an 
ion-channel formation in membranes of mitochondria and adrenalin-containing vesicles of the 
sympathetic nervous system, the adrenal chromaffin cells (Mathew et al., 1981, Tachikawa et 
al., 1991). However, this activity could not be confirmed in the agar diffusion test. Iida and 
co-workers suggest that the channel-forming abilities of these rather short peptides may be 
related to a head-to-tail dimerization forming long helical rods that are long enough to span 
membranes (Iida et al., 1995).  
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5 General discussion 
Marine fungi are recognized as a valuable source for new and bioactive secondary metabolites 
that have the potential to lead to innovations in drug therapy (Haefner, 2003). The purpose of 
this study was thus to investigate marine fungal strains towards their secondary metabolism in 
order to find new and preferably bioactive compounds with an emphasis on cytotoxic and 
antimicrobial activity. From the screening program, five fungal strains with promising 
cytotoxic or antimicrobial activity were cultivated on large scale, the secondary metabolites 
produced were chemically characterized and their potential concerning cytotoxicity and 
antibacterial activity was investigated using bioassay-guided isolation.  
 
5.1 Exploring the chemical diversity of marine-derived fungi 
The spectrum of fungal metabolites ranges from polyketides and peptides to terpenes and 
heteroaromatic compounds which illustrates the extraordinary structural diversity of 
secondary metabolites produced by these microorganisms (Schneider et al., 2008). This is 
impressively demonstrated by the fact that metabolites belonging to different compound 
classes have been found in this project, including several new structures with very unusual 
carbon skeletons and complex stereochemistry. Even though a remarkable number of fungal 
natural products is already known, the potential of these microbes is far from being fully 
exploited.  
 
Investigations of fungal secondary metabolism show that the majority of the compounds 
produced by marine fungi belong to the class of polyketides and peptides (Keller et al., 2005), 
which precisely reflects the results of this study. While the anthraquinone derivatives 
pachybasin (18; Shibata et al., 1955) and chrysophanol (19; Howard & Raistrick, 1950) 
isolated from Alternaria japonica / strain 194 are rather small and simple polyketides formed 
by eight acetate units (see 4.4), the trichodermanones (1-4) found in Trichoderma 
saturnisporium / strain 54 possess a complicated, bridged ring system, most likely originating 
from two different polyketide units that have undergone a Diels-Alder cycloaddition (see 4.2). 
Peptidic structures have been found as well, e. g. beauvericin (14; Hamill et al., 1969) in 
Beauveria bassiana (see 4.3) and peptides similar or identical to the trichorovins (20, 21) in 
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Trichoderma harzianum / strain 714 (see 4.5). Furthermore, tetramic acid derivatives like the 
newly found beauversetin (11) from Beauveria bassiana / strain 321 or sch210972 (15; Yang 
et al., 2006) from Microdiplodia sp. / strain 405 (see 4.3) are examples for heteroaromatic, 
alkaloid compounds originating from two separate biogenetic units, a polyketide part and an 
amino acid part (Fig. 5-1-1) .  
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Figure 5-1-1:  Examples for polyketides and PKS/NRPS derived compounds isolated during this 
study. 
 
All structural classes described in this study were found in several fungal organisms. 
However, a single fungus is also capable of producing secondary metabolites via different 
biosynthetic pathways, each of which seems to be regulated depending on the nutritional 
offers from its surrounding and the ecological needs of the microbe, e. g. defence. Attempts to 
optimize culture conditions for strain 54 (see 4.2.1) clearly showed that this also applies to 
laboratory conditions, i. e. variation of culture media can result in a significant change of 
secondary metabolite production and thus in changes in the 1H-NMR spectra. In fact, it is 
pachybasin (18) trichodermanone A (1) 
beauversetin (11) sch210972 (15) 
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known that fungi possess the ability to adapt to the surrounding ecosystem in an extremely 
fast manner (Turner, 1971). Hence, the chemical diversity observed for fungal strains is 
related to a high degree to the situation the microbes grow in. 
 
Regarding the incredible variability of the secondary metabolites produced by fungi that are 
known to date and the evidence for genetic regulation mechanisms (Shwab et al., 2008; 
Stadler & Keller, 2008), it is undoubtedly the case that fungi – marine as well as terrestrial – 
possess the ability to produce a plethora of many more different compounds than those that 
are known to date. 
 
5.2 Evaluation of the screening and isolation procedure – variations in 
fungal secondary metabolism 
Bioassay-guided isolation of secondary metabolites represents a rational and time-effective 
tool for the discovery of new and bioactive compounds. Further advantages of this method are 
obvious: it prevents novel compounds from being overlooked that often remain undetected in 
studies where the investigator only identifies compounds he is familiar with (Duke et al., 
2000; Rimando et al., 2001). Moreover, it can allow detecting unknown bioactivities or side 
effects of existing compounds or compound mixtures. Such substances or extracts may have 
been noted for different bioactivities before, but have not been tested for the target(s) used for 
bioassay-guided isolation. On the other hand, the bioassays used in this study possess a rather 
general validity and do not target specific functions. The monolayer tumor assay for example 
only considers the percentage of surviving cells and not the exact mechanism of action of the 
test compounds. When a specific cellular function is recognized as a target for potential 
therapeutics and used for screening, there are more chances for the isolation of compounds 
that serve as tools for biological research or lead structures for clinical medicines. 
 
During this study, fungal strains were first cultured on a small scale for screening purposes. 
After extraction with EtOAc, their crude extracts were investigated by spectroscopic methods 
and biological assays, e. g. cytotoxic and antimicrobial tests. Those strains showing 
bioactivities and promising analytical data from the screening were then cultivated again on a 
large scale, and investigated based on the results of the screening extract. Isolation of the 
secondary metabolites was done bioassay-guided in the cases where the results from the 
screening could be reproduced during large scale cultivation. 
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Bioassay-guided isolation has proven to be successful for the isolation of the secondary 
metabolites from Trichoderma harzianum (see 4.5), where the causing agents of the 
cytotoxicity could be determined as the peptaibol mixtures 20 and 21. However, for several 
fungi subjected to this study, e. g. Microdiplodia sp. and Alternaria japonica, the promising 
cytotoxic results from the screening could not be re-gained after large scale cultivation and 
fractionation of the crude extract, which made the approach of bioassay-guided isolation of 
cytotoxic compounds not possible. This phenomenon is frequently observed under laboratory 
conditions and is due to the above-mentioned adaptation of the investigated microorganisms 
to their surrounding conditions and the resulting change in secondary metabolism (Williams 
et al., 2008), since culture conditions cannot be strictly controlled in the laboratory. There are 
several explanations for this change of metabolism, even though the exact mechanisms of 
how fungi regulate their secondary metabolite production are not understood in every detail 
yet. Fungi are extremely variable organisms – strains obtained from different sources, 
although appearing morphologically identical, will not necessarily behave in the same way 
biologically (Turner, 1971). Variation can already occur within one given strain: frequent 
mutations in the genome can determine a complete change in secondary metabolite 
production. Additionally, and presumably even more frequently, the expression of bioactive 
secondary metabolite genes can be downregulated when those compounds are no longer 
needed for survival of the organism, which is often the case under standard laboratory 
conditions (Casselton & Zolan, 2002). Thus, the secondary metabolites will not be produced 
anymore even though their genetic information is still intact. The number of putative natural 
product biosynthetic pathways found in fungal genomes typically exceeds the total of natural 
products observed under laboratory culture conditions (Williams et al., 2008). Pertinent 
examples highlighting this phenomenon are found among Aspergillus spp. (Nierman et al., 
2005), Neurospora crassa (Galagan et al., 2003), and Magnaporthe grisea (Dean et al., 
2005). These biosynthetic gene clusters can be described as “silent” genes.  
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Evidence for the regulation of biosynthetic gene clusters on the molecular level came from 
studies indicating that responses to environmental signals are transmitted through pathway-
specific regulatory genes; so-called narrow- and broad-domain transcription factors (Keller et 
al, 2005). Narrow pathway-specific regulators are usually found in the gene cluster and 
positively regulate gene expression. Those transcription factors encoded in the biosynthetic 
gene cluster are often Zn(II)2Cys6 zinc binuclear cluster proteins and so far only found in 
fungi (Proctor et al., 1995; Woloshuk et al., 1994; Fernandes et al., 1998). Responses to 
environmental signals are transmitted through broad-domain factors that are often Cys2His2 
zinc-finger global transcription factors mediating carbon, nitrogen or pH signalling 
(Tudzynski et al., 1999; Ehrlich et al., 2003; Tilburn et al., 1995). Broad transcription factors 
can positively or negatively regulate secondary metabolite production and are conserved in all 
fungi. Regulation by both narrow- and broad-domain transcription factors ensures that 
secondary metabolite pathways can respond to the demands of general cellular metabolism 
and the presence of specific pathway inducers. 
 
In order to keep variations of the fungal strains as small as possible and thus to obtain 
reproducible results, the cultivation conditions for screening and large scale cultivation have 
been optimized and adjusted. Nevertheless, in some cases a significant change in secondary 
metabolism was observed after large scale cultivation, resulting in different results from 
cytotoxicity tests of the crude extracts compared to the screening results. Obviously, minor 
and unintentional changes of the culture conditions beyond the simple fact of medium 
composition can be responsible for such changes, e. g. minimal light or temperature 
differences. This fact impressively underlines how capriciously fungal strains can behave and 
how fast they adapt to their surroundings. 
 
In conclusion, bioassay-guided isolation is a valuable approach for target-oriented work, but 
depends heavily on the metabolic stability of the investigated organisms when they have to be 
re-cultured. This includes mutations, but also regulation of secondary metabolism within the 
microorganism. If this requirement cannot be met, other approaches for the isolation of 
bioactive secondary metabolites must be considered, possibly including methods of 
bioinformatics or molecular biology and genetics. 
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5.3 Biological activity 
One of the goals of natural products research including the present study is to find substances 
which are suitable as lead structures in the development of drugs or crop protection products. 
Moreover, a characterization of the selected fungal strains in terms of chemical diversity and 
biological activity was intended.  
 
One of the products isolated during this study exhibited promising bioactivities that have not 
been published before. The tetramic acid derivative sch210972 (15) from Microdiplodia sp., 
which has been published to be a chemokine receptor antagonist (Yang et al., 2006) revealed 
a significant inhibition of human leucocyte elastase as well as antimicrobial properties against 
B. megaterium in the bioassays performed during this study. The antibiotic activity 
corresponds well with published data for similar structures containing the tetramic acid 
moiety, like tenuazonic acid (active against B. megaterium; Gitterman, 1965), pachydermin 
(mild activity against B. subtilis; Lang et al., 2006) or ravenic acid (active against S. aureus; 
Michael et al., 2004). HLE inhibition however, is reported here for the first time. Tetramic 
acids thus represent a new structural type for the development of HLE inhibitors. 
Additionally, the HLE inhibitory bioactivity further enlarges the broad spectrum of 
bioactivities known for tetramic acids so far.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-1-2:  Examples for tetramic acid derivatives possessing antibiotic activities. 
 
ravenic acid 
tenuazonic acid 
pachydermin 
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Bioassay-guided isolation of the cytotoxic crude extact of Trichoderma harzianum revealed 
the presence of cytotoxic peptaibol mixtures (see 4.5). Moreover, the new compound 
beauversetin (11), which has been isolated from a cytotoxic fraction of B. bassiana, is likely 
to possess the desired activity as well (see 4.3). Unfortunately, due to the very small amount 
isolated (2.6 mg) the activity could not be entirely verified. The structurally novel tricho-
dermanones (1-4) elucidated during this study were tested in several bioassays, but did not 
show significant bioactivities (see 4.2). However, an in-silico-screening revealed the 
probability of the trichodermanones to possess TNF α-inhibitory potential. This should be 
verified in further studies. 
 
The results obtained help to complete the chemical characterization of the investigated fungal 
strains. Furthermore, the bioactivity spectrum of several compounds that have been isolated 
from other strains before could be enlarged by the discovery of new bioactivities. Thus, even 
the re-isolation of already known compounds (dereplication) can be useful in order to gain 
more insight into natural products characteristics, e. g. their bioactivities. These results, the 
discovery of novel secondary metabolites and new bioactivities will lead to a better 
understanding of fungal secondary metabolite production. 
 
5.4 The future of natural products research on marine-derived fungi 
In many cases the biosynthetic capability of microbes is by far not reflected in the observed 
metabolite spectrum when they are cultivated under standard conditions (Bergmann et al., 
2007). Thus, strategies must be elaborated to explore such secondary metabolites, whose 
biosynthesis is encoded by “silent” genes (Williams et al., 2008). While under certain 
laboratory conditions, fungi may produce highly cytotoxic secondary metabolites, in different 
surroundings (e. g. provoked by a slightly different medium composition, or simply changes 
of light or temperature) the secondary metabolite production can change rapidly and the 
resulting compounds are completely different, concerning both the structures as well as the 
bioactivities. This high potential of variations in secondary metabolite production among 
fungi, while being disadvantageous for bioassay-guided isolation, on the other hand opens 
new possibilities of finding new and bioactive natural products and can be used to push 
secondary metabolite production into a desired direction. 
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Based on this evidence, Zeeck and co-workers have developed the OSMAC (One Strain 
Many Compounds) approach, a rather undirected, but successful tool to gain access to 
“hidden” natural products. It is based on the alteration of cultivation conditions with the aim 
of achieving different secondary metabolite profiles (Bode et al., 2002; Bode et al., 2000). 
This can be the change of media components, differentiation of pH value, temperature, or 
duration of cultivation, but also co-cultivation with another microorganism or the addition of 
biosynthetic precursors or enzyme inhibitors to the growth medium. The latter was 
successfully realized by Crews and co-workers. Applying the OSMAC approach by 
incubating the fungus together with the potent F-actin inhibitor jasplakinolide as specific 
pathway inducer, new cytotoxic chaetoglobosins from the sponge-derived fungus Phomopsis 
asparagi have been isolated. The most potent compound, chaetoglobosin-510, disrupted actin 
microfilaments at 1 µg L-1 (Christian et al., 2005). 
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Figure 5-1-3:  The cytotoxic chaetoglobosin-510, isolated via the OSMAC approach (Christian et 
al., 2005). 
 
Until recently, research into fungal secondary metabolism was dominated by establishing 
screening programmes for chemically new and biologically active products, as was done in 
this study as well. Biochemical and genetic studies were generally rare due to the formidable 
technical challenges: the enzymes that synthesize secondary metabolites are often only 
present in minute quantities, and many of the producing fungal species lacked the sexual 
systems that were required for classical genetic analysis and mapping. Only after the finding 
of recombination via horizontal gene transfer, the first molecular genetic analysis and reverse 
genetics became possible (Casselton & Zolan, 2002). 
 
chaetoglobosin-510 
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Enormous advances in molecular biology, bioinformatics and genomics have enabled the 
development of new techniques that can overcome these challenges, and revealed that the 
genes encoding specific fungal enzymes responsible for the building of secondary metabolites 
are clustered and often located near telomeres (Keller et al., 2005). Hence, new strategies for 
the isolation of fungal secondary metabolites are nowadays shifting away from the purely 
chemical analysis towards making use of the genomic information in order to find metabolites 
which are encoded by “silent” (also referred to as “orphan” or “cryptic”) gene clusters (Gross, 
2007). To date, a significant number of fungal PKS and NRPS gene clusters have been 
identified although it is suspected that an intriguingly high number of gene clusters is still 
waiting to be discovered.  
 
The detection of silent pathways can be achieved by different methods. A very successful way 
is a genomics-guided approach which consists of an in silico-screening of a complete genome 
sequence in order to find consensus motifs, e. g. of certain PKS or NRPS modules, which are 
known to be the major biosynthetic gene clusters found in fungi (Gross, 2007). This way, 
Scherlach and co-workers have isolated four novel prenylated quinoline alkaloids, the 
aspoquinolines, from the filamentous fungus Aspergillus nidulans that are only produced 
under defined growth conditions (Scherlach et al., 2006). By scanning the publicly available 
genome sequence of the fungus, the presence of several gene copies of a putative anthranylate 
synthase led to re-investigation of the microbe by analytical methods and resulted in the 
discovery of the novel secondary metabolites.  
 
 
 
 
 
 
 
 
Figure 5-1-4:  Chemical structure of aspoquinoline A, which has been discovered by a genomics-
guided approach (Scherlach et al., 2006). 
 
Without the availability of complete sequence data of a microorganism, a PCR based search 
for distinct modules can be undertaken. As soon as a silent genomic region has been 
identified, it can be further analyzed to unveil the corresponding secondary metabolite. This 
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can be done for example by inactivation studies or the genomisotopic approach (Kunze et al., 
2005; Gross et al., 2007). These methods have been successfully applied for bacteria and 
myxobacteria, and will hopefully also help to discover new fungal secondary metabolites in 
the near future. 
Metagenomics is another key approach for the unravelling of silent pathways, especially to 
those microorganisms that cannot be cultivated under laboratory conditions (Schloss & 
Handelsman, 2005). Heterologous expression would be an elegant way to uncover the 
products correlated to the genomic information. 
 
The field of chemical and analytical methods that can be described as the “classical” approach 
in natural products research has rendered outstanding services to the finding of new and 
bioactive natural products in the last years, and continue to be invaluable for this issue. 
Recently, new methods in the field of molecular biology and genomics have made enormous 
advances and significantly contributed to the field of natural products research. However, to 
continue the successful work, both methods should not be regarded as separated approaches. 
For example, it is not yet possible to predict the structure of any polyketide of a fungal PKS 
through analysis of domain and motif structures alone (Keller et al., 2005). Heterologous 
expression and chemical analysis of the produced compound are needed to completely 
describe the natural product in question. Thus, the strategy to combine both methods of 
molecular biology and natural products chemistry will open new horizons in natural products 
research and provide new resources for the discovery of novel and bioactive natural products. 
 
 Summary  
 
103
6 Summary 
Many drugs in clinical use are natural products or natural product-derived. Among the most 
important natural products in drug therapy are many antibiotics, lipid-lowering agents based 
on the structure of lovastatin and anticancer drugs like paclitaxel and derivatives thereof. The 
need for new lead structures for the treatment of severe diseases like cancer or inflammatory 
ailmens continues, since established therapies are inadequate or lose their efficacy due to drug 
resistance. 
 
The marine habitat has been proven to be a rich source for both macro- and microorganisms 
that produce novel and often highly bioactive natural products. Hence, the investigation of the 
secondary metabolite spectrum of marine fungi represents a valuable approach in the search 
for new and bioactive natural products. The present study thus focused on the investigation of 
marine-derived fungi with the aim to isolate bioactive secondary metabolites via a bioassay-
guided isolation strategy. Special emphasis was placed on new structural types and their 
ability to act as antitumor or, in second priority, antibiotic agents.  
 
From the cytotoxicity screening program undertaken within the Institute for Pharmaceutical 
Biology, five fungal strains with cytotoxic activity towards cancer cells and interesting 
chemical features, i. e. 1H-NMR and LC-MS data, were chosen for detailed investigation. 
Two of these strains were sponge-derived while three have been isolated from the inner tissue 
of marine algae. From these fungal cultures altogether 19 compounds and two peptidic 
mixtures have been isolated and their structures characterized. They belonged to different 
structural classes, e. g. polyketides (pachybasin, chrysophanol, and more), peptides 
(beauvericin, peptaibols) and PKS/NRPS derived compounds (beauversetin and sch210972). 
 
The sorbicillin derivatives trichodermanones A-D (1-4) were obtained from the sponge-
derived fungus Trichoderma saturnisporium. The trichodermanones are remarkable because 
of their unprecedented carbon skeletons, most likely originating from two different polyketide 
units that have been connected via a Diels-Alder reaction during biosynthesis. One of these 
units can be described as sorbicillin-like, characterized by a cyclohexanone ring with an 
attached six-membered side chain (sorbyl moiety). The second structural part which is a 
pyrane ring in 1-3 and a lactone ring in 4 is possibly triketide-derived (ring C). The structures 
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of the compounds, including the absolute stereochemistry, were determined by interpretation 
of their spectroscopic data (1D and 2D NMR, CD, MS, UV and IR) and molecular modelling 
calculations. The relative configuration of the sorbicillin part of the molecule as well as of 
ring C could be solved by selective NOE measurements, respectively. A CD spectrum gave 
evidence for the absolute configuration of the sorbicillin part. However, the spatial 
relationship between the sorbicillin substructure and ring C and thus the configuration at C-7 
and C-8 remained unclear at first. This problem could be solved by molecular modelling 
calculations. Four preferred conformations were calculated for the trichodermanones A-C 
taking into account all possible configurations at C-7 and C-8. As it was clear that the 
conformation of the non-sorbicillin part of the structures and thus 1H-1H coupling constants 
were dependent on the configuration at C-7, the magnitude of proton-proton coupling 
constants were considered and compared with those calculated for the modelled molecules by 
the Karplus equation. The results obtained finally led to the deduction of the absolute 
configuration of the trichodermanones 3R, 5S, 6R, 7R, 8R, 10S for trichodermanone A, 
3R, 5S, 6R, 7S, 8R, 10S for trichodermanone B and 3R, 5S, 6R, 7S, 8R, 10S for tricho-
dermanone C.  
 
 
 
 
 
 
 
 
 
 
Tetramic acid derivatives are an important class of nitrogen heterocycles with a pyrrolidine-
2,4-dione core structure as a key structural motif and a wide range of bioactivities. Bioassay-
guided isolation of the cytotoxic crude extract of Beauveria bassiana led to the isolation of 
the new cytotoxic tetramic acid derivative beauversetin. A compound of the same structural 
type, the tetramic acid sch210972 was found to be produced by the sea weed-derived fungus 
Microdiplodia sp. and showed strong human leucocyte elastase (HLE) inhibitory activity with 
an IC50 value of 1.04 µg mL-1. HLE plays a role in several inflammatory diseases such as 
pulmonary emphysema or chronic bronchitis and thus represents an important target for drug 
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research. Our results show that tetramic acids represent a new lead structure for the 
development of potent HLE inhibitors. 
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The compounds isolated during this study impressively demonstrate the structural diversity of 
fungal secondary metabolites. The trichodermanones are a formidable example for unique 
structures from marine-derived fungi. Furthermore, the discovery of tetramic acids as 
inhibitors of HLE showed that the marine habitat is a rich source for structurally novel 
compounds which can serve as lead structures for the development of novel and innovative 
drugs. 
 
beauversetin (11) sch210972 (15) 
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8 Appendix 
Trichodermanone A (1), 1H-NMR, 500 MHz, (CD3)2CO. 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C-NMR, 75 MHz, (CD3)2CO. 
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Trichodermanone B (2), 1H-NMR, 500 MHz, (CD3)2CO. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C-NMR, 125 MHz, (CD3)2CO. 
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Trichodermanone C (3), 1H-NMR, 500 MHz, (CD3)2CO. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C-NMR, 75 MHz, (CD3)2CO. 
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Trichodermanone D (4), 1H-NMR, 500 MHz, (CD3)2CO.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C-NMR of 4, 75 MHz, (CD3)2CO. 
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Rezishanone C (5), 1H-NMR, 300 MHz, (CD3)2CO. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C-NMR, 75 MHz, (CD3)2CO. 
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Beauversetin (11), 1H-NMR, 500 MHz, CD3OD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C-NMR, 75 MHz, CD3OD. 
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Mixture of furane derivatives (12, 13), 1H-NMR, 500 MHz, CD3OD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C-NMR, 75 MHz, CD3OD. 
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HMBC of 12, 13, 300 MHz, CD3OD. 
 
 
1H-1H COSY of 12, 13, 300 MHz, CD3OD. 
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Beauvericin (14), 1H-NMR, 300 MHz, CD3OD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C-NMR, 75 MHz, CD3OD. 
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Sch210972 (15), 1H-NMR, 300 MHz, (CD3)2CO). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C-NMR, 75 MHz, (CD3)2CO. 
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 4-oxo-benzenebutanoic acid (16), 1H-NMR, 300 MHz, (CD3)2CO). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C-NMR, 75 MHz, (CD3)2CO. 
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WF-3681 (17), 1H-NMR, 300 MHz, (CD3)2CO). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C-NMR, 75 MHz, (CD3)2CO. 
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Pachybasin (18), 1H-NMR, 300 MHz, CDCl3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C-NMR, 75 MHz, CDCl3. 
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